Comparison between CHI, SHI, and NHS model.
\r\n\tAccording to research, even in developed societies, at least three-quarters of the society has a health-related complaint, but only one-third of them consult a physician for help. Access to professional healthcare is low for several reasons. These reasons are poverty, lack of education or health literacy, lack of job skills, lack of a country's natural resources, lack of scientific knowledge, lack of infrastructures such as roads, communication lines, efficient government, false beliefs, bad environmental conditions such as pollution of water, soil, and air, racial, ethnic, sexual, and age discrimination in employment practices, corrupt or incompetent governments, poorly developed economy.
\r\n\tIn today's conditions, the increase in natural disasters due to global climate change and the loss of existing natural resources such as water and soil deteriorates good environmental conditions. Disasters cause acute health problems such as injuries and infections, and access to health services becomes difficult in disaster situations. For these reasons, professional health services should be well planned in crisis and disaster situations. Social justice and equity should be considered in planning. In recent years, we have seen an increase in violence and wars around the world. Wars caused by man-made disasters take away people's right to life and right to health. In addition, extraordinary situations such as wars, famine, floods, soil erosion, hurricanes, earthquakes, and droughts cause large migrations and make access to health services difficult. On the other hand, nuclear power plants threaten people's lives in some regions due to wars. It has also become difficult to provide health services for professional healthcare providers.
Various methods of cryopreservation of blood cells are generally known and have been used for a long time. The storage of blood in the frozen state presented one of the alternative ways of storing blood components; this possibility was intensively explored in the 1950s and 1960s, when the shelf life of nonfrozen red blood cells did not exceed 21 days at those times. This time limitation significantly reduced flexibility of usage of RBC products and contributed to their dramatically high and wasteful expiration reaching up to 30%. The short shelf life of the RBCs resulted in the transfusion services not being able to meet demands of quickly evolving surgical disciplines, particularly cardiovascular surgery and radical surgical oncology. In military and emergency healthcare, utilization of these 3-week products as a way of creating blood supplies was even more complicated, almost unthinkable. The storage of frozen red blood cells therefore presented a great prospect [1].
Nevertheless, some areas with a need to long-term storage of the blood cells still remained—for example, being the military transfusion, emergency transfusion service, storage of rare blood cells, or special autologous transfusion programs. Blood substitution and blood supply are permanent strategic and logistic problems of the military medical services across the world arising from the blood, has a limited shelf life and need the special transport and use conditions. The same problem must solve the national healthcare authorities in programs of the national blood crisis policy, where to get a huge amount of blood supply any time at any place in the case of disaster, terrorist attack, and war. The therapeutic problems in immunohematology cases can solve by stock of rare blood, storage of autologous blood for patients with rare erythrocyte or platelets antigens, and storage of autologous blood for patients with red blood cell alloantibodies or HLA/HPA platelets refractoriness with no chance to use common blood. All mentioned demands highly correspond with stock of frozen blood. New global security risks exalt this problem to all-society relevancy [1].
If the short storage time and shelf life can be problematic at fresh red blood cells, this disadvantage is greatly enhanced at standard platelet products. Fresh platelet, stored at a temperature of 20–24°C, have shelf life of 5–7 days. This excludes the production of larger supplies and makes their production, distribution, and use, logistically more difficult. This is particularly limiting for trauma centers, urgent hospital admissions, and intensive care units dealing with massive bleeding. Extremely difficult is the implementation of platelet transfusion in war medicine, remote areas, and pre-hospital care. Uncontrollable bleeding is the second leading cause of death in trauma patients. In battlefield casualties with severe blood loss, platelets are often deficient because of blood loss and because the platelets get consumed during blood clotting.
In many instances, frozen platelets are given prophylactically and autologous or HLA/HPA compatible frozen platelet transfusions have become an important part of the supportive care of leukemic patients at this institution during maintenance and reinduction therapy, when alloimmunization is frequently present.
The primary role of cryopreservation is the long-term preservation of cells and tissues while at the same time protecting them from the undesirable effects of frost. Already in 1866, Pouchet first described that frozen erythrocytes are destroyed after thawing [2].
During the changing process of aqueous solutions into solid state, it is water that changes its state of matter first. Water crystals are created from pure water, while the space between them is filled with concentrated electrolyte. This leads to cellular dehydration and to the pH change and those mechanisms destroy cell membrane before mechanical injury is caused by ice crystals [1, 3, 4].
Protection of cells from freezing is achieved by adding cryoprotective substances. Since these cryoprotectants usually cause a significant increase in osmolality, it is nevertheless necessary to have all the procedures monitored, and to have osmotic changes under control, in order to avoid an irreversible damage to cellular structures and membranes caused by them [1].
Mainly,
This cryoprotectans, previously rarely used, are no longer used for cryopreservation of blood [20, 21, 22, 23, 24].
Platelets may be frozen using various types of cryoprotectants: intracellular (DMSO and glycerol) or extracellular (HES and dextran). HES and dextran were found to be poor cryoprotectives, PLTs cryopreserved in glycerol gave lower yields and poor in vitro viability compared with those cryopreserved in DMSO, which is most suitable cryoprotectant for platelets.
Djerassi et al. [25] were the first to report on the use of 5% dimethyl sulfoxide and cooling at 1°C/min for successful cryopreservation and transfusion of human platelets. To avoid the effects related to the cryoprotectant itself (e.g., nausea, vomiting, local vasospasm, garlic-like taste, and body odor), Lundberg et al. [26] have introduced a post-thaw washing step. A method used by Schiffer et al. [27] has become the “standard” method for this purpose.
In 1956, Klein et al. reported the use of previously frozen platelets in an actively bleeding thrombocytopenic patient and ever since numerous studies have been reported on both the in vitro and in vivo efficacies of cryopreserved platelets [28]. Since Schiffer et al.’s 1976 study on the use of autologous platelets for the treatment of patients with leukemia, relevant studies until 1990s showed that the platelets were damaged to a significant extent by the freezing process that decreased their efficacy when compared to fresh platelets [27]. These results were supported by other in vitro studies that assessed the platelets’ primary hemostatic functions. It has been demonstrated that the in vivo hemostatic functions of cryopreserved APCs were superior to the fresh preserved platelets [29] and reported the procoagulant changes in the frozen-treated platelet membrane surfaces [30].
The most widely used method for the platelets cryopreservation is freezing at 5–6% DMSO concentration at −80°C, with their storage at −65°C and lower. The method of platelet cryopreservation using DMSO was developed in the 1970s by Robert Valeri with the support of the US Navy’s research program as a possible substitute for native platelets for transfusion therapy for wounded service personnel during military operations [19, 29, 31]. In the original method, the DMSO and the supernatant needed to be washed out upon thawing, making the method arduous for use in field hospitals. Over time, the procedure was adjusted to remove the excess DMSO and supernatant prior to freezing [29, 32, 33]. The method is simple, inexpensive, and requires no special equipment. For transport over long distances, transport containers filled with dry ice are used. Alternatively, it is possible to use transport active freezers providing a temperature of <−65°C. As the storage temperature of DMSO-cryopreserved platelets ranges from −80 to −65°C, the use of liquid nitrogen (or its fumes) is not necessary, and mechanical deep freezers can be used for storage instead. After thawing, the platelets are suspended in thawed plasma and there is no need to wash out the cryoprotectant. Original method can be modified by resuspension of thawed platelets in saline (0.9% NaCl) or plasma additive solution (PAS).
The procedures
To the collecting container with standard unit with apheresis or buffy-coat pooled platelets, preferably leucodepleted, with >280 × 109 PLT/unit and in the original donor plasma, is added 75 ml 25% solution DMSO in 0.9% NaCl resulting to 5–7% final DMSO concentration in platelet unit (Figure 1).
The container with PLTs + DMSO is connected with smaller container (using sterile connection device), where platelets will freeze (Figure 2).
Centrifugation 20 min, use soft spin (Figure 3).
Gently removing of supernatant using the manual extractor and using visual control, tube sealing and labeling. The final product has 13–15 ml (Figures 4 and 5).
Freezing in cartoon box at −80°C, storage at −65 to −80°C (Figures 6 and 7).
Add DMSO to collected fresh platelets.
Sterile connection of the container with PLTs contained DMSO to container for freeze.
A large volume centrifuge for platelets centrifugation.
Removal of supernatant from platelets before freezing using the manual extractor.
Removed supernatant (left) and the final platelets product prepared for freezing (right).
Platelets before freezing.
An example of −80°C portable freezing box.
The procedures for
One unit of frozen platelets and one unit of frozen plasma are thawed to 34–36°C. It is recommended to check the concordance of temperatures of both products at surface temperature, using contactless infrared thermometer (Figures 8–11).
The thawed platelets are gently “spreading” using a gauze with emphasis to flatten of potentially aggregates (Figure 12).
Connecting container with thawed platelets and container with thawed plasma, using sterile connection device. The plasma is transferred into the platelets by gentle stirring. Transferring the contents of the bags back and forth (three times) ensures a perfect mix of the products and a homogeneous suspension is obtained (Figures 13 and 14).
Note, the visual control is focused mainly on the presence/absence of aggregates. In thawed, previously frozen platelets, usually is not seen swirling phenomenon. The explanation is, that thawed thrombocytes are activated, altered in shape, with numbers of pseudopodia on the surface that make this optical phenomenon impossible.
The final product (in the original platelet container) is detached from the plasma container, labeled and released for transfusion. The thawing and reconstitution does not exceed 30 min.
If plasma is used for reconstitution, as described above, the type AB plasma mixed with type O platelets is used. However, for reconstitution, other solutions can be used, PAS or saline.
The shelf life of thawed and reconstituted platelets depends on the technical procedure of adding DMSO. It is usually 6 hours because of a non-sterile connection of a glass bottle with DMSO.
Frozen platelets.
Frozen plasma.
Plasma/platelets thawer.
Temperature check.
Spreading of thawed platelets.
Sterile connection of thawed platelets with thawed plasma.
Transfer thawed plasma to thawed platelets.
Platelets stored frozen are efficient in primary hemostasis after thawing. They efficiently contribute to stop bleeding as a part of complex transfusion therapy or damage control resuscitation in polytrauma patients and patients with massive bleeding. Some studies confirm that after reconstitution, the life span of platelets cryopreserved using DMSO in human circulation is comparable to native platelets in vitro [29, 34, 35, 36, 37].
The most widely used method is the reconstitution of cryopreserved platelets in thawed plasma, but there seems to be no significant difference between platelets reconstituted in other solutions, such as saline or PAS [29, 38, 39].
Although the platelets stored by cryopreservation are efficient in hemostasis, they are affected by a number of functional defects during storage and preparation for transfusion. The process of freezing and thawing causes changes in platelet morphology and affects their function. Approximately 15% of cryopreserved platelets lost surface-bound GPIb, while there was no measurable loss of GPIIB/IIIa during cryopreservation. The cryopreserved platelets also showed a significant decrease in aggregation to ristocetin, but no loss of response to the stronger agonist, thrombin. Even though these defects are of a minor clinical relevance and the cryopreserved platelets were shown to be safe and effective for the treatment of abnormal bleeding, it is still necessary to reckon with these changes [22, 40, 41].
In cytometric observation, the frozen platelets contain about 85% of the particles in the microparticle area and only about 15% of the particles in the platelets region. For fresh platelets, this ratio is about 20% of microparticles and 80% of platelets. The question is to what extent higher amounts of microparticles are responsible for the observed higher hemostatic efficacy of cryopreserved platelets. Additionally, cryopreserved platelets are considerably smaller than fresh platelets and have a lower perpendicular light scattering, reflecting not only their smaller size but also their spherical shape. Unlike the fresh platelets, frozen platelets are highly positive for Annexin V binding. This may contribute to their higher thrombin generation potential and lower circulating ability [42].
Platelet cryopreservation is associated with the release of platelet membrane particles and thrombin generation. The microparticles formed by cryopreservation carry phosphatidylserine on their surfaces and thus are phenotypically different from those found before freezing. Cryopreserved platelets have greater endogenous thrombin potential than fresh platelets [43].
This confirms the fact that platelet activation release of substances that potentiate the growth of thrombin generation occurs during cryopreservation and subsequent reconstitution. This is a set of reasons why the frozen platelets exhibit increased coagulation activity leading to faster clot formation with a concurrent decrease in clot strength. Such fact is confirmed by the thromboelastography measurements. The TEG curves evidently show a decrease in coagulation initiation time, that is, higher coagulation activity and faster clot formation (wider angle α), and a reduced maximum clot strength (MA), which is, however, still sufficient for initial coagulation [44, 45, 46]. The coagulation activity is further increased by reconstitution in frozen plasma. Platelets resuspended in such a way are more efficiently coagulative than, for example, platelets resuspended in additive solution.
Some observations by electron microscopy show plasma membrane disruption and vesiculation in 60% of thawed platelets. More than half of cryopreserved platelets exhibit signs of platelet membrane damage with a significant increase in its fluidity, induced by 6% DMSO alone and by the freezing and thawing process.
To speed up cryopreserved platelet reconstitution in plasma, it is possible to use plasma stored at a temperature of 4°C, meaning that the products can then be used within 15 min. However, for patients requiring the platelets for an indication other than hemostasis, resuspension in additive solution may be a suitable choice.
The administration of cryopreserved platelets usually is not followed by any increase in blood platelet count, as in the case for fresh platelets and corrected count increments for platelets (CCI) is hard to use for evaluation of treatment effectiveness. This may be due to several causes. First is the broken structure and shape of thawed platelets associated with the higher amount of phosphatidylserine on their surface, which apparently contributes to the lower survival time in circulation and lead to their immediate consumption in hemostasis. Another reason may be their more difficult resolution for the blood count analyzers. In the group of patients transfused with fresh platelets, a significantly higher platelet count was found in peripheral blood when compared to the patients transfused with cryopreserved platelets. Other laboratory and clinical parameters (clinical efficacy) are comparable. However, this is one of the reasons why cryopreserved platelets are recommended mainly for substitution in conditions associated with severe bleeding, and less for prophylactic treatment of hematological thrombocytopenia.
It is also necessary to keep in mind the differences associated with cryopreserved platelets, such as membrane-bound coagulation factors V and X, increased formation of thromboxane B2, and the significant presence of the released microparticles. However, these observations are unlikely to have great clinical relevance for the use of cryopreserved platelets in the treatment of massive bleeding, particularly in terms of any possible influence on their coagulation activity [47]. Similarly, clinical efficacy is not influenced by decreased platelet counts in the preparation or lower recovery rate after thawing. These are adequately compensated by a comparable life span in the patient’s circulation, as shown in healthy volunteer studies published previously.
In the studies published so far, no severe reactions were reported following administration of frozen platelets and this was confirmed by our observation. Furthermore, no negative effect of increased coagulation activity of the cryopreserved platelets was observed [36, 48].
Cryopreservation and storage of frozen platelets may significantly (or unlimitedly) prolong their shelf life. Thus, frozen platelets provide long-term accessibility in situations where fresh and native products are not available and there is no way of obtaining them. The production of cryopreserved platelets is not technologically demanding, and furthermore, they can be easily thawed and reconstituted.
Early massive and complex transfusion therapy, excluding erythrocyte substitution, contributes significantly to coagulopathy correction and the alleviation of bleeding. The rapid administration of the whole spectrum of transfusion products is proven to have a positive impact on patient survival. Therefore, most current transfusion protocols and hemostatic resuscitation procedures are based on the co-administration of erythrocytes and plasma, supplemented with platelet transfusion [29, 49].
Platelet availability for the timely application of a modern massive transfusion protocol during the first “golden hour” following the onset of bleeding is often problematic. Furthermore, most hospitals cannot afford to have native platelets permanently available due to their short expiration and high price. Even university hospitals and large trauma centers may experience a limited availability of platelets in cases of urgent need for large quantities. Ensuring the availability of platelets in field military hospitals, namely in current international military operations, is even more problematic.
Although the given thawing and reconstitution procedure describes the use of a sterile bag tubing welder when connecting the platelet and plasma bags, the use of a sterile connection device is not necessary. In blood banks that do not have this technology, it is advantageous to connect the bags using simple tubing with spikes at both ends.
The relatively short shelf life of cryopreserved platelets (2 years) as blood product is based on the European directive and has no real evidential basis. The data from a study conducted in a laboratory at the Militaire Bloedbank in Leiden, the Netherlands, are currently being processed [50]. According to the preliminary information, these data support the possibility of extending the shelf life to at least 4 years. The preparation shelf life of 6 h, after thawing and reconstitution, is based on the fact that the process of adding the DMSO before freezing does not take place in a completely closed system and at the same time, it allows the use of tubing to add the resuspension media. If the DMSO was commercially manufactured in a plastic bag as a medical device using a sterile welder, it would be possible to extend the shelf life of the cryopreserved platelets even after reconstitution.
In recent years, there has been a relatively large renegotiation of interest in cryopreserved platelets as a promising blood product, which is being used, tested, and validated in a number of countries and institutions.
Therefore, cryopreserved platelets constitute a suitable alternative, which has been used by the Dutch Military Health Service and other countries for some time [4, 50, 51, 52, 53, 54]. The easy availability, compatibility, safety, and efficacy of the cryopreserved products significantly improved survival rates of patients with war injuries treated during international missions at Dutch army field hospitals in 2001–2012. Another advantage is the possibility of storing HLA-/HPA-matched platelets and rare platelets, as well as autologous platelets.
See Refs. [48, 51, 52, 53, 55, 56, 57].
Yes, for the military and for clinical civil studies.
In civil society so far only in clinical trials.
In 6% DMSO, 24–48 h after storage at −65 to −90°C, exp. 2 years.
Plasma reconstitution at 30°C, exp. 6 h.
Long service life.
Decreased expiration and thrombo-thawing on the patient.
Increased procoagulant activity—an advantage for pac. with severe bleeding.
Yes, for the army.
In civilian, not in a prospective military operation.
In 6% DMSO.
Storage at −65 to −90°C, exp. 2 years.
Plasma reconstitution, exp. 6 h.
Long shelf life, protrobotic potential.
Currently no, recently for studies.
Not yet, prospectively.
In 6% DMSO.
Storage at −65 to −90°C, exp. 2 years.
Plasma reconstitution, exp. 4 h.
Long shelf life, immediate availability, the ability to store rare platelets.
Yes.
Yes, so far Military University Hospital Prague, prospective in trauma centers.
In 6% DMSO, within 2 h of collection.
Storage at −65 to −90°C, exp. 2 years.
Plasma reconstitution at 32°C, exp. 6 h.
Immediate availability, procoagulant activity—suitable for severe bleeding.
Stock of platelets for field military medical service.
Yes—from 2015.
Yes: rare HPA/HLA platelets, severe bleeding.
In 5% DMSO.
Storage at −65 to −90°C, exp. 2 years/−180°C, exp. 3 years.
Plasma reconstitution at 32°C, exp. 6 h.
Platelets availability when native platelets are not available, platelets used for field military care and in remote areas.
Currently no, it is considered to be produced in the military blood transfusion service.
Not yet.
In 6% DMSO.
Storage at −65 to −90°C, exp. 2 years.
Plasma reconstitution/PAS.
Long service life.
Procoagulant activity—suitable for severe bleeding.
Thrombocyte assurance in remote areas.
Yes.
Heavy bleeding (obstetrical bleeding), autologous platelets.
In 5–6% DMSO.
Storage at −65 to −90°C.
Availability, hemostatic effect.
Yes.
Yes: 11–13,000 T.D./year (10–12% of total platelet consumption).
If there are no native, special indications: neonates and intranasal transfusions at immunological thrombocytopenia, HLA/HPA rare platelets.
In 5% DMSO, within 24 h of collection.
Storage at −65 to −90°C, exp. 1 year/−140°C, exp. 2 years.
Reconstitution in 0.9% NaCl, exp. 2 h at 20–24°C.
Immediate availability, possibility of provision of HLA/HPA rare platelets.
Long service life.
Yes—only for research yet.
No, they are looking forward.
In 6% DMSO, from BC.
Storage at −65 to −90°C, exp. 2 years.
Plasma reconstitution at 32°C, exp. 4 h.
Long shelf life, total expiration and destruction of platelets, platelet collapse in the absence of native.
Yes.
Yes, HLA typed platelets.
In 6% DMSO.
Storage at −65 to −90°C, exp. 2 years.
Plasma reconstitution at 32°C, exp. 4 h.
Providing HLA typified thrombocytes.
Yes, only in military blood bank.
Yes, only in the field military health service.
In 6% DMSO, from apheresis, 24 h after collection.
Storage at −65 to −90°C, exp. 4 years.
Plasma reconstitution at 32°C, exp. 6 h.
Providing comprehensive hemostatic therapy in field military health.
Yes.
Cardio surgery.
In 5% DMSO.
Storage at −65 to −80°C, exp. 2 years.
Plasma reconstitution.
Maintain a stock of platelets, platelets HPA/HLA compatible.
Yes
The strategic location of Turkey mandates governmental medical organizations in establishing frozen platelet and erythrocyte stocks.
In 4–6% DMSO.
Storage at −65 to −80°C, exp. 2 years.
Plasma reconstitution/0.9% NaCl.
Maintain a stock of platelets, military use.
Yes, so far only for studies, in perspective after FDA approval.
Not yet, only in studies.
In 4–6% DMSO.
Storage at −65 to −90°C, exp. 2 years.
Plasma reconstitution/0.9% NaCl.
Maintain a stock of platelets and stock of HLA-typed platelets, military use.
The cryopreservation of blood is a method, which solves various problems in blood transfusion service. The main application is in military medicine and blood crisis policy, but also in special transfusiology fields, such as the storage of rare red blood cells and long-term storage of autologous blood. Due to modern procedures, which allow for prolonged shelf time after thawing and reconstitution of frozen blood, the use of frozen blood is now more flexible and less limited. Cryopreserved blood products are fully in comliance with European legislation [1].
Cryopreserved platelets have all the necessary prerequisites to constitute a product suitable for a possible wider application. Due to the extended shelf life, it is possible to create sufficient supplies of these transfusion products without a substantial cost increase. Cryopreserved platelets are suitable for both civilian and military use, particularly for the treatment of acute conditions associated with massive bleeding, when no permanent or sufficient supply of fresh platelets is available. Cryopreserved platelets act as a substitute for human platelets by helping the blood clotting mechanism in patients, who have a deficiency of platelets. Thawing and reconstitution is a simple procedure that takes no more than 30 min.
Cryopreserved platelets may find use in other indications, such as the autologous products, rare or HLA/HPA compatible platelets or in a wide range of nontransfusion applications. Due to their low production cost, the use of cryopreserved platelets does not represent a significant increase in the cost of transfusion therapy. Our work and previous studies suggest that cryopreserved platelets are efficient, effective, and safe.
Despite the stated advantages, the use of cryopreserved platelets in clinical practice has hitherto been rather limited and scarce. Their wider application is hindered by relatively little data on their in vitro attributes or on the comparison with the attributes of fresh platelets, and the complete absence of clinical studies evaluating their efficacy in vivo.
Leaders of the world have committed to achieve universal health coverage (UHC) goal number 3.8 of the sustained development goals (SDGs) by 2030. This means that people of any country should have access to at least essential health services regardless of their income or social groups within a country. Two indicators are used in monitoring the UHC covering indicator 3.81 of service coverage and indicator 3.8.2 of catastrophic health spending [1, 2] Service coverage ensures that everyone should have essential health services when she/he needs them and catastrophic health spending ensures that no one goes bankrupt when paying for health care to meet his/her need. Recent monitoring by three global organizations, the World Health Organization, the World Bank, and the OECD have demonstrated the progress of the incidence of catastrophic health spending with two thresholds percentage of 10% and 25% of the total household incomes or expenditures [3]. Catastrophic health spending (CHS) is an important measure of out-of-pocket (OOP) expenditure by household members that should not exceed 10% of income [4]. Above that, the household may become impoverished. The indicator 3.8.2 is essential to protect people from being poor due to the consumption of health care when ill health or accident occurs.
Market mechanism in health care means that everyone must purchase health care out of his/her pocket and the health care providers set prices above the production costs to get profit and develop the business. Because of the uncertain needs for health care, ability to pay at the prices set by the sellers (health care providers) market mechanism tend to impoverish people. The WHO reported that 996 million people in the world (13.2%) spend more than 10% of their budget on OOP health care consumption [5]. Health economic literatures have long acknowledged that health care is not normal goods because of its unique characteristics. For the normal goods or services, market mechanism leads a fair competition and to adequate supplies the people could purchase, lower prices and higher quality of products. One of the requirements of perfectly competitive market is the information symmetry between the purchasers and the sellers.
There are three main distinct characteristics of health care needs that make fully competitive market mechanism of health care does not function well [6]. The first characteristic is
There are two main types of health insurance based on the mandatory or voluntary transfer of risks. The mandatory insurance scheme is called social health insurance, which is normally used in national health insurance (NHI), while the voluntary joining health insurance is called commercial health insurance. Another way of managing risk of uncertainty in health care is to cover all health care needs by the state budget like in the National Health Service (NHS) scheme in the United Kingdom [9].
Health insurance can be differentiated according to the financing function of the health system. There are systems mainly financed by taxes while others are mainly financed by social health insurance (SHI). Both income tax and SHI contribution are compulsory in the world. Both SHI and income tax are taken proportionally from income or salaries. To top up those mandatory contributions, in many countries, there are markets for private (voluntary) health insurance, except in few countries such as the United States where private health insurance is the main source of health care financing for working population. However, for the elderly population with high health risks, the US health care system uses mandatory of a kind of SHI (the Medicare Program) [9, 10].
The second distinct characteristic of health care is the very high
What about health insurance market? It has also high information asymmetry. At the individual level, an individual has very little knowledge about the probability of health care needs covered by a health insurance policy, its appropriate premium, and how good is the insurance policy paying health care providers. The main drawback of private or commercial health insurance schemes is how an individual (called a prospect) understands his or her health risks and how much of these risks can be transferred, method of risk calculation to set premium, and how the insurer underwrites the health risks. Therefore, private health insurance is normally sold as group insurance, either as the main health care protection or as a top-up coverage in the NHI or NHS scheme. In commercial health insurance, the purchasing mechanism for individuals follows the “take it or leave it” business model. Both commercial health insurance and health care do not meet the requirement of independent decision to purchase health care or health insurance. Since the nature of transaction of commercial insurance is voluntary and insurers are companies seeking profits, commercial health insurance schemes are always multipayers. Every business entity has a freedom to enter the health insurance market. A health system that depends heavily on commercial health insurance will not achieve effective (cover all people or UHC) and efficient health system (a relative low portion of GDP is spent for health). Designing, marketing, and managing commercial health insurance require multiple professional workers, and the economy of scale will not achieve efficient system. Competition in health insurance market pushes insurers to create unique and competitive plans (health insurance products) leading to only portions of people or groups of people that may purchase. This condition absolutely will not achieve the law of a large number of the main predictable events of insurance principle.
The third distinct characteristic of health care is the
The combination of the three distinct characteristics of health care generates other unique health care needs called “patient ignorance, patient short-sighted, patient inability to pay, unfair health financing, and provider moral hazard or fraud.” In addition, because unmet health care needs could result in severe disability or death, health care consumption is a human right. Therefore, combination of those unique characteristics of health care needs requires collective efforts and public funding. The goal of 3.8 of SDGs, UHC is the global commitment to meet health care needs for everyone. One of the key element of UHC is public financing using insurance mechanisms or tax-funded system.
Generally, many people think health insurance is commercial insurance, which is a rational and good instrument to overcome uncertainty of health care needs, especially in high-cost health care. Not many people understand social health insurance (SHI) schemes as a solution to financing health care for everyone. Some Muslim leaders and scholars (those who are preaching Islamic religion) mistakenly consider health insurance as not meeting Sharia requirements. Some of them understand health insurance as a trade of intangible products which violates the principle of Sharia, the Islamic law. In a narrow definition, a health insurance policy is a commercial transaction between one party to an institution called insurer of an intangible product or service which consider
In wider definition of minimizing uncertainty, a publicly funded health care system such as the NHS can be considered providing health insurance for all people. When a country provides UHC using funding from general tax revenue, there is no uncertainty of health care needs at an individual level in the country applying NHS model. However, not all countries are able to establish and finance an NHS model. Many low and middle-income countries are looking for financing schemes that gradually meet the health care needs of all people in the country. One of the essential elements of the objectives of UHC is equity health financing, which means that financing for health care by individual is based on the ability of an individual to contribute (to pay), but the health care services consumed by the individual are based on his/her health care needs. This equitable financing can only be achieved by publicly funded system, based on tax-funded or social health insurance (SHI) mechanism. Once there is a pool-fund, the purchasing of health care for everyone should be managed effectively and efficiently.
Some country leaders may be trapped to rely on commercial health insurance (CHI) instead of SHI. Basically, both CHI and SHI share the characteristics of insurance contracts. The key difference between CHI and SHI is nature of entering into insurance contract. The CHI is voluntary transaction while the SHI is mandatory for individuals to enter into an insurance contract. Another key difference between CHI and SHI is the premium for CHI is based on the levels of health risks while the premium (often called “contribution”) for SHI is based on a proportion of individual income or salary. The SHI can be implemented using multiple or single organizations. If the SHI scheme is administered by a single organization, a government agency, or a quasi-government organization, it is called a National Health Insurance (NHI) such as implemented in South Korea, Taiwan, the Philippines, and Indonesia. In many other countries, the SHI schemes are administered by various organizations such as implemented in Germany, French, and Japan.
An insurance contract stipulates right and obligation that bind each party. There are four distinct insurance contracts applicable to CHI and SHI:
Due to the uncertain nature of health care needs, the obligation of an insurer (both CHI and SHI) is
The 2nd characteristic of the insurance contract is
The 3rd characteristic of insurance contract is
It is this contract that differs from the term of prepayment that is often used in some health care financing papers. The term “prepaid health care” was first used by Paul Ellwood in the USA for the Health Maintenance Organization (HMO) contract in 1973 just to get acceptance by the American Medical Association that opposed health insurance scheme at that time [14]. The term “prepayment” may be misleading to describe health care financing because of this aleatory contract. The term prepaid or prepayment as often used in mobile phone business is appropriate because the payer can consume phone service up to the amount paid in advance.
The last characteristic of insurance contract is called
Financing UHC using traditional health insurance concept of CHI poses significant problems. The double information asymmetry of health care need and health insurance contract create market failure to ensure everyone is covered to meet his/her health care needs. The unique characteristics of health care needs and the long-term externality of having healthy lives as the main requirement for individual economic productivity push all governments to ensure health services are available for everyone regardless of individual income or social status. The COVID-19 Pandemic has demonstrated how strong the health sector affected the World economy which declined by 3.4 percent in 2020 [15]. The COVID-19 pandemic emphasizes the importance of UHC as a set of the 3.8 Goal of SDGs. The UHC can only be achieved if there is sufficient public health financing.
There are three possible public financing for health that allow UHC with different efficiency levels. The first automatic covering all people is the tax funded or NHS model; the second one is the mature SHI model; and the third one is a combination of the two. Often SHI model is complemented with tax funded subsidies for the low-income people. The administration of funds of the SHI model varies widely across the countries with dominant SHI model. Currently, no country with CHI model could fully achieve UHC. There are differences in funding UHC based on health financing mechanisms as shown in the following Table 1.
Element/Issue | CHI | SHI–NHI | NHS |
---|---|---|---|
Participation | Voluntary | Mandatory | Automatic |
Ability to cover all population (UHC) | Almost impossible | Highly likely | Always |
Inclusiveness | Almost impossible | Highly likely | Always |
Benefit package | Vary widely, designed by the insurer | Relatively uniform for all people | Uniform for all |
Nature of benefit package | Based on demand, Consideration of profit, mostly not comprehensive | Based on health care needs, mostly comprehensive | Subject to amount of state funds and health needs |
Risk transfer /funding method | Risk-based premium | Income-based contribution, normal percentage of income | Income tax and other state taxes |
Insurer | Private for-profit or not-for-profit | Private organization not for profit or government/public entity | The government |
Number of payers | Always multiple | Single or multiple | Always single there are regional payers in some cases |
Legal basis | Various regulations on various aspects | Mostly by single regulation for all people or group of people | Constitution or state budget regulation |
Administrative costs | High | Very low | Mix with state expenses |
Adverse selection | Inherent, likely | Avoided | Avoided |
Comparison between CHI, SHI, and NHS model.
The main problem of CHI is the voluntary nature of participation. People are shortsighted and health risks cannot be predicted by individual. Therefore, there is unlikely that an individual will purchase CHI or private health insurance coverage. But when someone suffers from a chronic condition, then that person will demand CHI creating adverse or anti selection. The insurer that aims for profit making certainly will undertake rigorous underwriting to ensure no adverse selection. The insurer may inherently design a benefit package, terms, and conditions for prospects to minimize adverse selection. Certainly, people suffering from a chronic condition elderly and those who have congenital health problems will not be able to purchase health insurance. In addition, because the premiums (prices) are set based on health risks of individuals or small groups, higher risks of individuals or small groups must pay higher premiums. This certainly excludes low-income people from having health insurance coverage. Commercial health insurance charge loading fees is significantly high, depending on the size of the group insured that can vary up to 34% of the total premiums paid [16]. Therefore, CHI model fails to achieve UHC.
Because of the market failure of CHI and health care market, the option to cover everyone is by public financing. Public financing is based on mandatory contribution and based on the proportion of income or wealth. There are only two funding mechanisms of publicly funded health care, which are the SHI model and the NHS model.
The SHI model could apply for certain group of employed population. For example, before the implementation of NHI in Indonesia, the civil servants were covered by Askes—the SHI scheme for government employees and the private employees were covered by another SHI scheme called Jamsostek. Another example is Thailand, private employees are covered under Social Security Scheme administered by the Ministry of Labor, and the informal sector is covered by a tax fund administered by the National Health Security Office Taiwan [17]. The Philippines, South Korea, and Indonesia used to have several SHI schemes before they were integrated into a single national SHI called NHI. The level of contribution for the NHI model is normally uniform, a portion of salary for all employees. In Indonesia, current contribution is 5% of monthly income, shared by employees (1%) and employers 4%. In Germany, with multiple sickness funds, current contribution levels at around 14.6%, shared 50: 50 by employers and employees [18].
The United Kingdom initiated the NHI model in 1911 and then started the NHS in 1948 administered by the state. The NHS model is normally funded by progressive income taxes, which often exceed 50% of monthly income for the high tier of income. Low and middle-income countries often have problems in collecting and enforcing high progressive income tax. The maximum level of income taxes in European Countries that implement NHS varies from 43% in Italy to 56.95% in Finland [19]. Certainly, many low- and middle-income countries (LMICs) could afford this model. But, still some LMICs such as Sri Lanka apply the NHS model even though the income tax level has been relatively low at 18%.
As an option to cover health care needs, many LMICs could start SHI model based on employment. The SHI was first introduced in Germany, called statutory health insurance, by Otto von Bismarck the chancellor of liberal party in 1883 [20]. However, at that time, Von Bismarck mandated contributions to pay income loss of a laborer who was suffering from serious sickness and unable to work for income. At that time most labor forces were based on daily paid work. Now, the SHI covers health care costs, which vary from limited hospitalization to comprehensive medical and family benefit. In Germany, since the SHI concept was introduced, there are multiple funds called sickness funds but in decreasing number [21]. In many countries, most SHI started to mandate large-size employers such as civil servants and private employers with more than 100 employees to contribute a portion of incomes to cover defined health care benefits. South Korea [22], Indonesia [7], Taiwan [23], and the Philippines [24], for example, started to mandate public and formal sector employees, years before mandating the informal sector to contribute to the single-payer NHI.
In most LMICs where tax-funded system is not the option taken by the political leadership, SHI schemes can be a good choice to ensure equitable access to essential health care in LMICs. The SHI model can be gradually implemented for employed population for partial health benefits that the population can afford. Indonesia started SHI for civil servants in 1968 and then for private employees in 1993 and finally for everybody in 2014 [7]. China also introduced this social insurance model starting for employed groups. The challenges in implementing SHI for whole population are collecting contributions for the informal sector. The informal sector or non-waged earners do not have a regular monthly income. In LMICs, the proportion of non-waged earners is generally very high, more than 50%. Therefore, scaling up to cover the whole population to achieve UHC in LIMCs may take decades. One option is to subsidize the informal sector from the government budget, integrated to the NHI. When a country implementing SHI became a high-income country, normally the SHI model is continued to be implemented as happened in Germany, Korea, Japan, the Philippines, and Taiwan.
The choice of administrators of the SHI can be implemented by special SHI fund for special groups such as civil servants, private employees, teachers, farmers, etc. Multiple payer systems create possibility that some groups will have more coverage with higher contribution levels than others. Different SHI and different groups of population create oligo- or multi-payer systems that may provide problems in negotiating prices of health care from various providers. The Japan employer-based health insurance system creates a virtual single payer by forcing all SHI plans to purchase health care organized by Central Administrative Offices. Regardless of the plans, all Japan’s residents could go to the same health care providers. Implementing different SHI for different groups may create unequal benefits across different population groups and may not be acceptable in some countries. On the other hand, some small differences of contribution or preventive services like implemented in Japan are socially accepted [25]. Germany once had more than 5000 sickness funds; they now have less than 100 sickness funds. To ensure equity across different employment groups, Germany requires equalizing funds across different sickness funds [26]. South Korea once followed the German and Japan SHI model with multiple plans then in early 2000 integrated all SHI schemes into a single NHI model [14].
The politics, cultural values, social norms, and the national constitutions of countries play crucial roles in determining single- or multi-payer system of NHI. Indonesia also followed the Korean model, integrating SHI and social assistance schemes into a single NHI. The fight to establish a single NHI in Indonesia involved union strikes, extensive academic debates, and legal battle in the parliament and in the constitutional court [7]. Despite of the very high health expenditures, the USA has not achieved UHC. Only the elderly population is covered by the public fund of SHI model, called Medicare. The poor are covered by sharing of federal and state funds. The Obama Care is basically providing tax incentive for the informal sector to purchase CHI. Turkey integrates all SHI plans into a single NHI in 2008 by reforming the social security system [27].
In the last 30 years, four Asian countries started innovative health reform by establishment of a single-payer NHI. Taiwan started to implement the NHI in 1995, managed by the Bureau of the National Health Insurance of the Ministry of Health, providing comprehensive health care benefits [28]. Then, the Philippines followed in 1997 by establishing PhilHealth, the NHI Corporation attached to the Ministry of Health providing inpatient care only [29]. South Korea integrated more than 300 SHI plans into the NHI Service in 2000 providing comprehensive benefits with relatively high cost-sharing [30]. Indonesia followed enacting the national social security reform including the NHI in 2004 with comprehensive health care benefits, including preventive care. However, the political battles delayed the implementation of the NHI scheme (called JKN,
Meeting the Constitution mandate, which normally provides the right to health care for everyone. When the Constitution requires that every citizen has the right to health care, a single NHI could purchase health care from public and private health care providers, providing equitable access to meeting health care needs. The NHS model often limits access to public health care providers, while the single-payer NHI ensures the same access to everyone using any health care resources in the country.
The single-payer NHI has the biggest (monopsony) power to purchase health care from any health care providers licensed in the country [7, 31]. With this monopsony power, the NHI has the power to apply strategic health purchasing or prospective payments to optimize effectiveness and efficiency of the NHI fund. The NHI can dictate prices of health care, drugs, and other medical supplies from public and private health care providers. Hence, a single-payer NHI has strong power to make health system efficient.
A single NHI provides uniform procedures and benefits for everybody in the countries ensuring optimum social justice [7, 31]. These uniform procedures create less laborious efforts to educate the public. People who used the benefits can be good agents to make other people know how to utilize the benefits. This scheme provides efficient administration system because everybody and every health care provider will use a standardized system. Claim procedures can be organized using a single standard mechanism creating a very efficient system.
A single NHI provides economic incentives for health care providers to expand the care in areas where previously there is a shortage of private healthcare providers if the prices set by the NHI meet the production costs. So, the government or regional governments do not need to worry about establishing new hospitals.
All health care uses and the claim payments can be recorded in a single database and trend of health care utilization effects of medical procedures or drugs, side effects, and pattern of health-seeking behavior can be observed. This huge database could facilitate a ton of clinical and implementation research.
The prices and procedures of procurements of medical supplies and drugs can be standardized. Indonesia develops e-Catalog system where pharmaceutical companies and medical suppliers openly bid with lower prices and high volume across the country. Industries will be willing to lower the prices of their product for high volume. In addition, open and transparent competition will further induce efficiency of the industries. Pharmaceutical industries selling patent drugs can negotiate and deal with innovative financing to supply a high volume of their products.
The administrative costs of running a single NHI become very small compared to high revenue and multi-payer systems. Certainly, the NHI has very low administrative expenses compared to CHI, which can absorb up to 25% of the total premium income. The administrative costs of NHI in Asia ranged from 1.8% in Taiwan to about 4% in Indonesia. Most Medicare programs in the US, Canada, and Australia also consume less than 4% of revenue. The average administrative expenses of the German’s sickness funds were also around 4% of the total revenues.
When the NHI already reaches its maturity, providing quality health care to all populations with no catastrophic health spending, the NHI can be national pride.
If we consider tax-funded NHS as also a single payer with the government as the payer, this single-payer system or tax-funded system also has the above advantages. Evidence shows that countries applying NHS model, such as the UK, Nordic countries, Italy, and Spain, spent less than 10% of their GDP to achieve universal health coverage. In contrast, the US with dominance CHI has spent above 16% of its GDP in the last 10 years with relatively similar health outcomes with those developed countries with NHS or single-payer NHI.
As an illustration, in Figure 1 we plot the index of health expenditures and infant mortality rates of three countries using 2011 as the base (index =1) and trend of decreasing IMR up to 2017. We use the World Bank data to illustrate the correlation between changes in health expenditures per capita and changes in IMR of Germany (blue dots), Japan (green dots), and the USA (orange dots). The figure illustrates that a virtual (quasi) single-payer health financing system in Japan had better performance in decreasing IMR with the same increase (change of index) from 2011 to 2017. Although this figure may not depict causal relationship, we can see the correlation is noted to be explored more.
Illustration of the correlation between index changes in health care expenditure (% GDP) with index changes in IMR of three countries between 2011 and 2017. 2011 index = 1.
We also provide Table 2 illustrating the same level of UHC Index of high-income countries, public health spending as % GDP, and IMR per 1000 live births from 2011 to 2017. Data from the World Bank and the UHC Monitoring is used to develop this table.
Countries | Year | Public finance for health, % GDP | Infant mortality rate | UHC index* 2019 |
---|---|---|---|---|
US—Multiple CHI dominance | 2011 | 7.9 | 6.10 | > = 80 |
2012 | 7.9 | 6.00 | ||
2013 | 8.0 | 6.00 | ||
2014 | 8.3 | 5.90 | ||
2015 | 8.5 | 5.80 | ||
2016 | 8.6 | 5.80 | ||
2017 | 8.6 | 5.70 | ||
UK—NHS single | 2011 | 7.1 | 4.3 | > = 80 |
2012 | 7.0 | 4.1 | ||
2013 | 7.8 | 4.0 | ||
2014 | 7.8 | 3.9 | ||
2015 | 7.7 | 3.8 | ||
2016 | 7.8 | 3.8 | ||
2017 | 7.6 | 3.8 | ||
Australia—NHS single | 2011 | 5.9 | 3.8 | > = 80 |
2012 | 5.9 | 3.6 | ||
2013 | 5.9 | 3.5 | ||
2014 | 6.1 | 3.4 | ||
2015 | 6.4 | 3.3 | ||
2016 | 6.3 | 3.2 | ||
2017 | 6.3 | 3.2 | ||
Italy—NHS single | 2011 | 6.8 | 3.3 | > = 80 |
2012 | 6.8 | 3.2 | ||
2013 | 6.8 | 3.1 | ||
2014 | 6.8 | 3 | ||
2015 | 6.7 | 3 | ||
2016 | 6.6 | 2.9 | ||
2017 | 6.5 | 2.8 | ||
Spain—NHS single | 2011 | 6.7 | 3 | > = 80 |
2012 | 6.5 | 2.9 | ||
2013 | 6.4 | 2.8 | ||
2014 | 6.4 | 2.8 | ||
2015 | 6.5 | 2.7 | ||
2016 | 6.4 | 2.7 | ||
2017 | 6.3 | 2.7 | ||
Japan—NHI single | 2011 | 8.9 | 2.3 | > = 80 |
2012 | 9.1 | 2.2 | ||
2013 | 9.1 | 2.1 | ||
2014 | 9.1 | 2.1 | ||
2015 | 9.2 | 2 | ||
2016 | 9.1 | 2 | ||
2017 | 9.2 | 1.9 | ||
Korea—NHI single | 2011 | 3.7 | 3.4 | > = 80 |
2012 | 3.7 | 3.3 | ||
2013 | 3.8 | 3.2 | ||
2014 | 3.9 | 3.1 | ||
2015 | 4.0 | 3 | ||
2016 | 4.2 | 2.9 | ||
2017 | 4.4 | 2.8 | ||
Germany—SHI multiple | 2011 | 8.1 | 3.4 | > = 80 |
2012 | 8.1 | 3.4 | ||
2013 | 8.3 | 3.3 | ||
2014 | 8.4 | 3.3 | ||
2015 | 8.5 | 3.3 | ||
2016 | 8.6 | 3.3 | ||
2017 | 8.7 | 3.3 | ||
France—SHI multiple | 2011 | 8.5 | 3.1 | > = 80 |
2012 | 8.6 | 3.1 | ||
2013 | 8.7 | 3.1 | ||
2014 | 8.9 | 3.1 | ||
2015 | 8.8 | 3.2 | ||
2016 | 8.8 | 3.2 | ||
2017 | 8.7 | 3.3 |
Comparison of Public Finance as % GDP and IMR of Some Developed Countries with different health financing Schemes 2011–2018. Processed from World Bank Data and UHC Monitor 2021.
*Coverage of essential health services (defined as the average coverage of essential services based on tracer interventions that include reproductive, maternal, newborn and child health, infectious diseases, non-communicable diseases and service capacity and access, among the general and the most disadvantaged population). The indicator is an index reported on a unitless scale of 0 to 100.
To ensure UHC and equitable access of at least essential health care for everyone in a country, public financing for health is absolutely needed. Public finance for health using single-payer scheme has a lot of advantages yielding more effective and more efficient financing schemes. Tax-funded, NHS model, or single-payer NHI model appears to be more effective and more efficient to produce expected outcomes of IMR. Multiple payer system of SHI appears somehow less effective and less efficient compared to the single-payer, monopsonist system. The authors recommend that LMICs that have not achieved UHC and are under consideration to reform health financing system may explore the possibility of introducing a single-payer health financing system. If a tax-funded (NHS) model is not possible, implementing SHI gradually to achieve an NHI would be a preferred choice. However, political battles need to be anticipated.
We do not have any conflict of interest. No fund from external authors is used for this chapter.
None.
IntechOpen aims to ensure that original material is published while at the same time giving significant freedom to our Authors. To that end we maintain a flexible Copyright Policy guaranteeing that there is no transfer of copyright to the publisher and Authors retain exclusive copyright to their Work.
',metaTitle:"Publication Agreement - Chapters",metaDescription:"IN TECH aims to guarantee that original material is published while at the same time giving significant freedom to our authors. For that matter, we uphold a flexible copyright policy meaning that there is no transfer of copyright to the publisher and authors retain exclusive copyright to their work.\n\nWhen submitting a manuscript the Corresponding Author is required to accept the terms and conditions set forth in our Publication Agreement as follows:",metaKeywords:null,canonicalURL:"/page/publication-agreement-chapters",contentRaw:'[{"type":"htmlEditorComponent","content":"The Corresponding Author (acting on behalf of all Authors) and INTECHOPEN LIMITED, incorporated and registered in England and Wales with company number 11086078 and a registered office at 5 Princes Gate Court, London, United Kingdom, SW7 2QJ conclude the following Agreement regarding the publication of a Book Chapter:
\\n\\n1. DEFINITIONS
\\n\\nCorresponding Author: The Author of the Chapter who serves as a Signatory to this Agreement. The Corresponding Author acts on behalf of any other Co-Author.
\\n\\nCo-Author: All other Authors of the Chapter besides the Corresponding Author.
\\n\\nIntechOpen: IntechOpen Ltd., the Publisher of the Book.
\\n\\nBook: The publication as a collection of chapters compiled by IntechOpen including the Chapter. Chapter: The original literary work created by Corresponding Author and any Co-Author that is the subject of this Agreement.
\\n\\n2. CORRESPONDING AUTHOR'S GRANT OF RIGHTS
\\n\\n2.1 Subject to the following Article, the Corresponding Author grants and shall ensure that each Co-Author grants, to IntechOpen, during the full term of copyright and any extensions or renewals of that term the following:
\\n\\nThe aforementioned licenses shall survive the expiry or termination of this Agreement for any reason.
\\n\\n2.2 The Corresponding Author (on their own behalf and on behalf of any Co-Author) reserves the following rights to the Chapter but agrees not to exercise them in such a way as to adversely affect IntechOpen's ability to utilize the full benefit of this Publication Agreement: (i) reprographic rights worldwide, other than those which subsist in the typographical arrangement of the Chapter as published by IntechOpen; and (ii) public lending rights arising under the Public Lending Right Act 1979, as amended from time to time, and any similar rights arising in any part of the world.
\\n\\nThe Corresponding Author confirms that they (and any Co-Author) are and will remain a member of any applicable licensing and collecting society and any successor to that body responsible for administering royalties for the reprographic reproduction of copyright works.
\\n\\nSubject to the license granted above, copyright in the Chapter and all versions of it created during IntechOpen's editing process (including the published version) is retained by the Corresponding Author and any Co-Author.
\\n\\nSubject to the license granted above, the Corresponding Author and any Co-Author retains patent, trademark and other intellectual property rights to the Chapter.
\\n\\n2.3 All rights granted to IntechOpen in this Article are assignable, sublicensable or otherwise transferrable to third parties without the Corresponding Author's or any Co-Author’s specific approval.
\\n\\n2.4 The Corresponding Author (on their own behalf and on behalf of each Co-Author) will not assert any rights under the Copyright, Designs and Patents Act 1988 to object to derogatory treatment of the Chapter as a consequence of IntechOpen's changes to the Chapter arising from translation of it, corrections and edits for house style, removal of problematic material and other reasonable edits.
\\n\\n3. CORRESPONDING AUTHOR'S DUTIES
\\n\\n3.1 When distributing or re-publishing the Chapter, the Corresponding Author agrees to credit the Book in which the Chapter has been published as the source of first publication, as well as IntechOpen. The Corresponding Author warrants that each Co-Author will also credit the Book in which the Chapter has been published as the source of first publication, as well as IntechOpen, when they are distributing or re-publishing the Chapter.
\\n\\n3.2 When submitting the Chapter, the Corresponding Author agrees to:
\\n\\nThe Corresponding Author will be held responsible for the payment of the Open Access Publishing Fees.
\\n\\nAll payments shall be due 30 days from the date of the issued invoice. The Corresponding Author or the payer on the Corresponding Author's and Co-Authors' behalf will bear all banking and similar charges incurred.
\\n\\n3.3 The Corresponding Author shall obtain in writing all consents necessary for the reproduction of any material in which a third-party right exists, including quotations, photographs and illustrations, in all editions of the Chapter worldwide for the full term of the above licenses, and shall provide to IntechOpen upon request the original copies of such consents for inspection (at IntechOpen's option) or photocopies of such consents.
\\n\\nThe Corresponding Author shall obtain written informed consent for publication from people who might recognize themselves or be identified by others (e.g. from case reports or photographs).
\\n\\n3.4 The Corresponding Author and any Co-Author shall respect confidentiality rights during and after the termination of this Agreement. The information contained in all correspondence and documents as part of the publishing activity between IntechOpen and the Corresponding Author and any Co-Author are confidential and are intended only for the recipient. The contents may not be disclosed publicly and are not intended for unauthorized use or distribution. Any use, disclosure, copying, or distribution is prohibited and may be unlawful.
\\n\\n4. CORRESPONDING AUTHOR'S WARRANTY
\\n\\n4.1 The Corresponding Author represents and warrants that the Chapter does not and will not breach any applicable law or the rights of any third party and, specifically, that the Chapter contains no matter that is defamatory or that infringes any literary or proprietary rights, intellectual property rights, or any rights of privacy. The Corresponding Author warrants and represents that: (i) the Chapter is the original work of themselves and any Co-Author and is not copied wholly or substantially from any other work or material or any other source; (ii) the Chapter has not been formally published in any other peer-reviewed journal or in a book or edited collection, and is not under consideration for any such publication; (iii) they themselves and any Co-Author are qualifying persons under section 154 of the Copyright, Designs and Patents Act 1988; (iv) they themselves and any Co-Author have not assigned and will not during the term of this Publication Agreement purport to assign any of the rights granted to IntechOpen under this Publication Agreement; and (v) the rights granted by this Publication Agreement are free from any security interest, option, mortgage, charge or lien.
\\n\\nThe Corresponding Author also warrants and represents that: (i) they have the full power to enter into this Publication Agreement on their own behalf and on behalf of each Co-Author; and (ii) they have the necessary rights and/or title in and to the Chapter to grant IntechOpen, on behalf of themselves and any Co-Author, the rights and licenses expressed to be granted in this Publication Agreement. If the Chapter was prepared jointly by the Corresponding Author and any Co-Author, the Corresponding Author warrants and represents that: (i) each Co-Author agrees to the submission, license and publication of the Chapter on the terms of this Publication Agreement; and (ii) they have the authority to enter into this Publication Agreement on behalf of and bind each Co-Author. The Corresponding Author shall: (i) ensure each Co-Author complies with all relevant provisions of this Publication Agreement, including those relating to confidentiality, performance and standards, as if a party to this Publication Agreement; and (ii) remain primarily liable for all acts and/or omissions of each such Co-Author.
\\n\\nThe Corresponding Author agrees to indemnify and hold IntechOpen harmless against all liabilities, costs, expenses, damages and losses and all reasonable legal costs and expenses suffered or incurred by IntechOpen arising out of or in connection with any breach of the aforementioned representations and warranties. This indemnity shall not cover IntechOpen to the extent that a claim under it results from IntechOpen's negligence or willful misconduct.
\\n\\n4.2 Nothing in this Publication Agreement shall have the effect of excluding or limiting any liability for death or personal injury caused by negligence or any other liability that cannot be excluded or limited by applicable law.
\\n\\n5. TERMINATION
\\n\\n5.1 IntechOpen has a right to terminate this Publication Agreement for quality, program, technical or other reasons with immediate effect, including without limitation (i) if the Corresponding Author or any Co-Author commits a material breach of this Publication Agreement; (ii) if the Corresponding Author or any Co-Author (being an individual) is the subject of a bankruptcy petition, application or order; or (iii) if the Corresponding Author or any Co-Author (being a company) commences negotiations with all or any class of its creditors with a view to rescheduling any of its debts, or makes a proposal for or enters into any compromise or arrangement with any of its creditors.
\\n\\nIn case of termination, IntechOpen will notify the Corresponding Author, in writing, of the decision.
\\n\\n6. INTECHOPEN’S DUTIES AND RIGHTS
\\n\\n6.1 Unless prevented from doing so by events outside its reasonable control, IntechOpen, in its discretion, agrees to publish the Chapter attributing it to the Corresponding Author and any Co-Author.
\\n\\n6.2 IntechOpen has the right to use the Corresponding Author’s and any Co-Author’s names and likeness in connection with scientific dissemination, retrieval, archiving, web hosting and promotion and marketing of the Chapter and has the right to contact the Corresponding Author and any Co-Author until the Chapter is publicly available on any platform owned and/or operated by IntechOpen.
\\n\\n6.3 IntechOpen is granted the authority to enforce the rights from this Publication Agreement, on behalf of the Corresponding Author and any Co-Author, against third parties (for example in cases of plagiarism or copyright infringements). In respect of any such infringement or suspected infringement of the copyright in the Chapter, IntechOpen shall have absolute discretion in addressing any such infringement which is likely to affect IntechOpen's rights under this Publication Agreement, including issuing and conducting proceedings against the suspected infringer.
\\n\\n7. MISCELLANEOUS
\\n\\n7.1 Further Assurance: The Corresponding Author shall and will ensure that any relevant third party (including any Co-Author) shall, execute and deliver whatever further documents or deeds and perform such acts as IntechOpen reasonably requires from time to time for the purpose of giving IntechOpen the full benefit of the provisions of this Publication Agreement.
\\n\\n7.2 Third Party Rights: A person who is not a party to this Publication Agreement may not enforce any of its provisions under the Contracts (Rights of Third Parties) Act 1999.
\\n\\n7.3 Entire Agreement: This Publication Agreement constitutes the entire agreement between the parties in relation to its subject matter. It replaces and extinguishes all prior agreements, draft agreements, arrangements, collateral warranties, collateral contracts, statements, assurances, representations and undertakings of any nature made by or on behalf of the parties, whether oral or written, in relation to that subject matter. Each party acknowledges that in entering into this Publication Agreement it has not relied upon any oral or written statements, collateral or other warranties, assurances, representations or undertakings which were made by or on behalf of the other party in relation to the subject matter of this Publication Agreement at any time before its signature (together "Pre-Contractual Statements"), other than those which are set out in this Publication Agreement. Each party hereby waives all rights and remedies which might otherwise be available to it in relation to such Pre-Contractual Statements. Nothing in this clause shall exclude or restrict the liability of either party arising out of its pre-contract fraudulent misrepresentation or fraudulent concealment.
\\n\\n7.4 Waiver: No failure or delay by a party to exercise any right or remedy provided under this Publication Agreement or by law shall constitute a waiver of that or any other right or remedy, nor shall it preclude or restrict the further exercise of that or any other right or remedy. No single or partial exercise of such right or remedy shall preclude or restrict the further exercise of that or any other right or remedy.
\\n\\n7.5 Variation: No variation of this Publication Agreement shall be effective unless it is in writing and signed by the parties (or their duly authorized representatives).
\\n\\n7.6 Severance: If any provision or part-provision of this Publication Agreement is or becomes invalid, illegal or unenforceable, it shall be deemed modified to the minimum extent necessary to make it valid, legal and enforceable. If such modification is not possible, the relevant provision or part-provision shall be deemed deleted.
\\n\\nAny modification to or deletion of a provision or part-provision under this clause shall not affect the validity and enforceability of the rest of this Publication Agreement.
\\n\\n7.7 No partnership: Nothing in this Publication Agreement is intended to, or shall be deemed to, establish or create any partnership or joint venture or the relationship of principal and agent or employer and employee between IntechOpen and the Corresponding Author or any Co-Author, nor authorize any party to make or enter into any commitments for or on behalf of any other party.
\\n\\n7.8 Governing law: This Publication Agreement and any dispute or claim (including non-contractual disputes or claims) arising out of or in connection with it or its subject matter or formation shall be governed by and construed in accordance with the law of England and Wales. The parties submit to the exclusive jurisdiction of the English courts to settle any dispute or claim arising out of or in connection with this Publication Agreement (including any non-contractual disputes or claims).
\\n\\nLast updated: 2020-11-27
\\n\\n\\n\\n
\\n"}]'},components:[{type:"htmlEditorComponent",content:"
The Corresponding Author (acting on behalf of all Authors) and INTECHOPEN LIMITED, incorporated and registered in England and Wales with company number 11086078 and a registered office at 5 Princes Gate Court, London, United Kingdom, SW7 2QJ conclude the following Agreement regarding the publication of a Book Chapter:
\n\n1. DEFINITIONS
\n\nCorresponding Author: The Author of the Chapter who serves as a Signatory to this Agreement. The Corresponding Author acts on behalf of any other Co-Author.
\n\nCo-Author: All other Authors of the Chapter besides the Corresponding Author.
\n\nIntechOpen: IntechOpen Ltd., the Publisher of the Book.
\n\nBook: The publication as a collection of chapters compiled by IntechOpen including the Chapter. Chapter: The original literary work created by Corresponding Author and any Co-Author that is the subject of this Agreement.
\n\n2. CORRESPONDING AUTHOR'S GRANT OF RIGHTS
\n\n2.1 Subject to the following Article, the Corresponding Author grants and shall ensure that each Co-Author grants, to IntechOpen, during the full term of copyright and any extensions or renewals of that term the following:
\n\nThe aforementioned licenses shall survive the expiry or termination of this Agreement for any reason.
\n\n2.2 The Corresponding Author (on their own behalf and on behalf of any Co-Author) reserves the following rights to the Chapter but agrees not to exercise them in such a way as to adversely affect IntechOpen's ability to utilize the full benefit of this Publication Agreement: (i) reprographic rights worldwide, other than those which subsist in the typographical arrangement of the Chapter as published by IntechOpen; and (ii) public lending rights arising under the Public Lending Right Act 1979, as amended from time to time, and any similar rights arising in any part of the world.
\n\nThe Corresponding Author confirms that they (and any Co-Author) are and will remain a member of any applicable licensing and collecting society and any successor to that body responsible for administering royalties for the reprographic reproduction of copyright works.
\n\nSubject to the license granted above, copyright in the Chapter and all versions of it created during IntechOpen's editing process (including the published version) is retained by the Corresponding Author and any Co-Author.
\n\nSubject to the license granted above, the Corresponding Author and any Co-Author retains patent, trademark and other intellectual property rights to the Chapter.
\n\n2.3 All rights granted to IntechOpen in this Article are assignable, sublicensable or otherwise transferrable to third parties without the Corresponding Author's or any Co-Author’s specific approval.
\n\n2.4 The Corresponding Author (on their own behalf and on behalf of each Co-Author) will not assert any rights under the Copyright, Designs and Patents Act 1988 to object to derogatory treatment of the Chapter as a consequence of IntechOpen's changes to the Chapter arising from translation of it, corrections and edits for house style, removal of problematic material and other reasonable edits.
\n\n3. CORRESPONDING AUTHOR'S DUTIES
\n\n3.1 When distributing or re-publishing the Chapter, the Corresponding Author agrees to credit the Book in which the Chapter has been published as the source of first publication, as well as IntechOpen. The Corresponding Author warrants that each Co-Author will also credit the Book in which the Chapter has been published as the source of first publication, as well as IntechOpen, when they are distributing or re-publishing the Chapter.
\n\n3.2 When submitting the Chapter, the Corresponding Author agrees to:
\n\nThe Corresponding Author will be held responsible for the payment of the Open Access Publishing Fees.
\n\nAll payments shall be due 30 days from the date of the issued invoice. The Corresponding Author or the payer on the Corresponding Author's and Co-Authors' behalf will bear all banking and similar charges incurred.
\n\n3.3 The Corresponding Author shall obtain in writing all consents necessary for the reproduction of any material in which a third-party right exists, including quotations, photographs and illustrations, in all editions of the Chapter worldwide for the full term of the above licenses, and shall provide to IntechOpen upon request the original copies of such consents for inspection (at IntechOpen's option) or photocopies of such consents.
\n\nThe Corresponding Author shall obtain written informed consent for publication from people who might recognize themselves or be identified by others (e.g. from case reports or photographs).
\n\n3.4 The Corresponding Author and any Co-Author shall respect confidentiality rights during and after the termination of this Agreement. The information contained in all correspondence and documents as part of the publishing activity between IntechOpen and the Corresponding Author and any Co-Author are confidential and are intended only for the recipient. The contents may not be disclosed publicly and are not intended for unauthorized use or distribution. Any use, disclosure, copying, or distribution is prohibited and may be unlawful.
\n\n4. CORRESPONDING AUTHOR'S WARRANTY
\n\n4.1 The Corresponding Author represents and warrants that the Chapter does not and will not breach any applicable law or the rights of any third party and, specifically, that the Chapter contains no matter that is defamatory or that infringes any literary or proprietary rights, intellectual property rights, or any rights of privacy. The Corresponding Author warrants and represents that: (i) the Chapter is the original work of themselves and any Co-Author and is not copied wholly or substantially from any other work or material or any other source; (ii) the Chapter has not been formally published in any other peer-reviewed journal or in a book or edited collection, and is not under consideration for any such publication; (iii) they themselves and any Co-Author are qualifying persons under section 154 of the Copyright, Designs and Patents Act 1988; (iv) they themselves and any Co-Author have not assigned and will not during the term of this Publication Agreement purport to assign any of the rights granted to IntechOpen under this Publication Agreement; and (v) the rights granted by this Publication Agreement are free from any security interest, option, mortgage, charge or lien.
\n\nThe Corresponding Author also warrants and represents that: (i) they have the full power to enter into this Publication Agreement on their own behalf and on behalf of each Co-Author; and (ii) they have the necessary rights and/or title in and to the Chapter to grant IntechOpen, on behalf of themselves and any Co-Author, the rights and licenses expressed to be granted in this Publication Agreement. If the Chapter was prepared jointly by the Corresponding Author and any Co-Author, the Corresponding Author warrants and represents that: (i) each Co-Author agrees to the submission, license and publication of the Chapter on the terms of this Publication Agreement; and (ii) they have the authority to enter into this Publication Agreement on behalf of and bind each Co-Author. The Corresponding Author shall: (i) ensure each Co-Author complies with all relevant provisions of this Publication Agreement, including those relating to confidentiality, performance and standards, as if a party to this Publication Agreement; and (ii) remain primarily liable for all acts and/or omissions of each such Co-Author.
\n\nThe Corresponding Author agrees to indemnify and hold IntechOpen harmless against all liabilities, costs, expenses, damages and losses and all reasonable legal costs and expenses suffered or incurred by IntechOpen arising out of or in connection with any breach of the aforementioned representations and warranties. This indemnity shall not cover IntechOpen to the extent that a claim under it results from IntechOpen's negligence or willful misconduct.
\n\n4.2 Nothing in this Publication Agreement shall have the effect of excluding or limiting any liability for death or personal injury caused by negligence or any other liability that cannot be excluded or limited by applicable law.
\n\n5. TERMINATION
\n\n5.1 IntechOpen has a right to terminate this Publication Agreement for quality, program, technical or other reasons with immediate effect, including without limitation (i) if the Corresponding Author or any Co-Author commits a material breach of this Publication Agreement; (ii) if the Corresponding Author or any Co-Author (being an individual) is the subject of a bankruptcy petition, application or order; or (iii) if the Corresponding Author or any Co-Author (being a company) commences negotiations with all or any class of its creditors with a view to rescheduling any of its debts, or makes a proposal for or enters into any compromise or arrangement with any of its creditors.
\n\nIn case of termination, IntechOpen will notify the Corresponding Author, in writing, of the decision.
\n\n6. INTECHOPEN’S DUTIES AND RIGHTS
\n\n6.1 Unless prevented from doing so by events outside its reasonable control, IntechOpen, in its discretion, agrees to publish the Chapter attributing it to the Corresponding Author and any Co-Author.
\n\n6.2 IntechOpen has the right to use the Corresponding Author’s and any Co-Author’s names and likeness in connection with scientific dissemination, retrieval, archiving, web hosting and promotion and marketing of the Chapter and has the right to contact the Corresponding Author and any Co-Author until the Chapter is publicly available on any platform owned and/or operated by IntechOpen.
\n\n6.3 IntechOpen is granted the authority to enforce the rights from this Publication Agreement, on behalf of the Corresponding Author and any Co-Author, against third parties (for example in cases of plagiarism or copyright infringements). In respect of any such infringement or suspected infringement of the copyright in the Chapter, IntechOpen shall have absolute discretion in addressing any such infringement which is likely to affect IntechOpen's rights under this Publication Agreement, including issuing and conducting proceedings against the suspected infringer.
\n\n7. MISCELLANEOUS
\n\n7.1 Further Assurance: The Corresponding Author shall and will ensure that any relevant third party (including any Co-Author) shall, execute and deliver whatever further documents or deeds and perform such acts as IntechOpen reasonably requires from time to time for the purpose of giving IntechOpen the full benefit of the provisions of this Publication Agreement.
\n\n7.2 Third Party Rights: A person who is not a party to this Publication Agreement may not enforce any of its provisions under the Contracts (Rights of Third Parties) Act 1999.
\n\n7.3 Entire Agreement: This Publication Agreement constitutes the entire agreement between the parties in relation to its subject matter. It replaces and extinguishes all prior agreements, draft agreements, arrangements, collateral warranties, collateral contracts, statements, assurances, representations and undertakings of any nature made by or on behalf of the parties, whether oral or written, in relation to that subject matter. Each party acknowledges that in entering into this Publication Agreement it has not relied upon any oral or written statements, collateral or other warranties, assurances, representations or undertakings which were made by or on behalf of the other party in relation to the subject matter of this Publication Agreement at any time before its signature (together "Pre-Contractual Statements"), other than those which are set out in this Publication Agreement. Each party hereby waives all rights and remedies which might otherwise be available to it in relation to such Pre-Contractual Statements. Nothing in this clause shall exclude or restrict the liability of either party arising out of its pre-contract fraudulent misrepresentation or fraudulent concealment.
\n\n7.4 Waiver: No failure or delay by a party to exercise any right or remedy provided under this Publication Agreement or by law shall constitute a waiver of that or any other right or remedy, nor shall it preclude or restrict the further exercise of that or any other right or remedy. No single or partial exercise of such right or remedy shall preclude or restrict the further exercise of that or any other right or remedy.
\n\n7.5 Variation: No variation of this Publication Agreement shall be effective unless it is in writing and signed by the parties (or their duly authorized representatives).
\n\n7.6 Severance: If any provision or part-provision of this Publication Agreement is or becomes invalid, illegal or unenforceable, it shall be deemed modified to the minimum extent necessary to make it valid, legal and enforceable. If such modification is not possible, the relevant provision or part-provision shall be deemed deleted.
\n\nAny modification to or deletion of a provision or part-provision under this clause shall not affect the validity and enforceability of the rest of this Publication Agreement.
\n\n7.7 No partnership: Nothing in this Publication Agreement is intended to, or shall be deemed to, establish or create any partnership or joint venture or the relationship of principal and agent or employer and employee between IntechOpen and the Corresponding Author or any Co-Author, nor authorize any party to make or enter into any commitments for or on behalf of any other party.
\n\n7.8 Governing law: This Publication Agreement and any dispute or claim (including non-contractual disputes or claims) arising out of or in connection with it or its subject matter or formation shall be governed by and construed in accordance with the law of England and Wales. The parties submit to the exclusive jurisdiction of the English courts to settle any dispute or claim arising out of or in connection with this Publication Agreement (including any non-contractual disputes or claims).
\n\nLast updated: 2020-11-27
\n\n\n\n
\n"}]},successStories:{items:[]},authorsAndEditors:{filterParams:{regionId:"2",sort:"featured,name"},profiles:[{id:"20567",title:"Prof.",name:"Ado",middleName:null,surname:"Jorio",slug:"ado-jorio",fullName:"Ado Jorio",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universidade Federal de Minas Gerais",country:{name:"Brazil"}}},{id:"83411",title:"Dr.",name:"Carmen",middleName:null,surname:"Feijoo",slug:"carmen-feijoo",fullName:"Carmen Feijoo",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Andrés Bello University",country:{name:"Chile"}}},{id:"72898",title:"Dr.",name:"Jaime",middleName:null,surname:"Romero",slug:"jaime-romero",fullName:"Jaime Romero",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Chile",country:{name:"Chile"}}},{id:"14015",title:"Dr.",name:"Juan Carlos",middleName:null,surname:"Moreno Piraján",slug:"juan-carlos-moreno-pirajan",fullName:"Juan Carlos Moreno Piraján",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/14015/images/system/14015.jpg",biography:"Dr. Juan Carlos Moreno-Piraján is a Full Professor, Department of Chemistry at the Universidad de los Andes (Bogotá, Colombia) and a Director of the Research Group of Porous Solids and Calorimetry. He is a chemist by profession who obtained his Ph.D. from the Universidad Nacional de Colombia, where his work was concentrated on the construction of the Tian-Calvet microcalorimeter, which was used for the characterization of activated carbons. Professor Moreno has spent his research career developing new materials for water purification. These interesting materials have been synthesized and he has also designed several microcalorimeters that have contributed to these studies. As a result of his research, Professor Moreno-Piraján has 160 publications. His main contributions can be found in the thermodynamic interpretation of solids and liquids, and in the information obtained from calorimetric measurements.",institutionString:"Universidad de los Andes",institution:{name:"Universidad de Los Andes",country:{name:"Colombia"}}},{id:"14764",title:"Dr.",name:"Marcelo L.",middleName:null,surname:"Larramendy",slug:"marcelo-l.-larramendy",fullName:"Marcelo L. Larramendy",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/14764/images/system/14764.jpg",biography:"Marcelo L. Larramendy, Ph.D., serves as Professor of Molecular Cell Biology at the School of Natural Sciences and Museum (National University of La Plata, Argentina). Appointed Senior Researcher of the National Scientific and Technological Research Council of Argentina. Former Member of the Executive Committee of the Latin American Association of Environmental Mutagenesis, Teratogenesis and Carcinogenesis. Author of more than 450 contributions, including scientific publications, research communications and conferences worldwide. Recipient of several national and international awards. Prof. Larramendy is a regular Lecturer at the international A. Hollaender Courses organized by the IAEMS and former guest scientist at NIH (USA) and the University of Helsinki, (Finland). He is an expert in Genetic Toxicology and is, or has been, referee for more than 20 international scientific journals. Member of the International Panel of Experts at the International Agency for Research on Cancer (IARC, WHO, Lyon, France) in 2015 for the evaluation of DDT, 2,4-D and Lindane. Presently, Prof. Dr. Larramendy is Head of the Laboratory of Molecular Cytogenetics and Genotoxicology at the UNLP.",institutionString:"National University of La Plata",institution:{name:"National University of La Plata",country:{name:"Argentina"}}},{id:"6375",title:"Prof.",name:"Margarita",middleName:null,surname:"Stoytcheva",slug:"margarita-stoytcheva",fullName:"Margarita Stoytcheva",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/6375/images/1631_n.jpg",biography:"Professor Margarita Stoytcheva graduated from the University of Chemical Technology and Metallurgy of Sofia, Bulgaria, with titles of Chemical Engineer and Master of Electrochemical Technologies. She has a Ph.D. and DSc. degrees in chemistry and technical sciences. She has acted in research and teaching in several Universities in Bulgaria, Algeria and France. From 2006. to the present she has participated in activities of scientific research, technological development and teaching in Mexico at the University of Baja California, Institute of Engineering, Mexicali, as a full time researcher. Since 2008. she has been a member of the National System of Researchers of Mexico. Her interests and areas of research are analytical chemistry and biotechnology.",institutionString:null,institution:{name:"Autonomous University of Baja California",country:{name:"Mexico"}}},{id:"79684",title:"Dr.",name:"Paola",middleName:null,surname:"Navarrete",slug:"paola-navarrete",fullName:"Paola Navarrete",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Chile",country:{name:"Chile"}}},{id:"14863",title:"Dr.",name:"Sonia",middleName:null,surname:"Soloneski",slug:"sonia-soloneski",fullName:"Sonia Soloneski",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/14863/images/system/14863.jpg",biography:"Sonia Soloneski has a Ph.D. in Natural Sciences and is Assistant Professor of Molecular Cell Biology at the School of Natural Sciences and Museum of La Plata, National University of La Plata, Argentina. She is a member of the National Scientific and Technological Research Council (CONICET) of Argentina in the Genetic Toxicology field, the Latin American Association of Environmental Mutagenesis, Teratogenesis and Carcinogenesis (ALAMCTA), the Argentinean Society of Toxicology (ATA), the Argentinean Society of Biology (SAB) and the Society of Environmental Toxicology and Chemistry (SETAC). She has authored more than 380 contributions in the field, including scientific publications in peer-reviewed journals and research communications. She has served as a review member for more than 30 scientific international journals. She has been a plenary speaker in scientific conferences and a member of scientific committees. She is a specialist in issues related to Genetic Toxicology, Mutagenesis, and Ecotoxicology.",institutionString:"National University of La Plata",institution:{name:"National University of La Plata",country:{name:"Argentina"}}},{id:"154185",title:"Dr.",name:null,middleName:null,surname:"Monteiro",slug:"monteiro",fullName:"Monteiro",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Institute of Animal Science and Pastures",country:{name:"Brazil"}}},{id:"151600",title:"Dr.",name:null,middleName:null,surname:"Vallejos",slug:"vallejos",fullName:"Vallejos",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Federico Santa María Technical University",country:{name:"Chile"}}},{id:"77248",title:"Dr.",name:null,middleName:null,surname:"Puerta",slug:"puerta",fullName:"Puerta",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Pontifical Xavierian University",country:{name:"Colombia"}}},{id:"71255",title:"Dr.",name:null,middleName:null,surname:"Torres-Bejarano",slug:"torres-bejarano",fullName:"Torres-Bejarano",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Mexican Institute of Petroleum",country:{name:"Mexico"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:8616},{group:"region",caption:"Middle and South America",value:2,count:7693},{group:"region",caption:"Africa",value:3,count:3005},{group:"region",caption:"Asia",value:4,count:15646},{group:"region",caption:"Australia and Oceania",value:5,count:1284},{group:"region",caption:"Europe",value:6,count:22554}],offset:12,limit:12,total:9140},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{topicId:"11"},books:[{type:"book",id:"11168",title:"Sulfur Industry",subtitle:null,isOpenForSubmission:!0,hash:"39d4f4522a9f465bfe15ec2d85ef8861",slug:null,bookSignature:"Dr. Enos Wamalwa Wambu and Dr. Esther Nthiga",coverURL:"https://cdn.intechopen.com/books/images_new/11168.jpg",editedByType:null,editors:[{id:"187655",title:"Dr.",name:"Enos",surname:"Wambu",slug:"enos-wambu",fullName:"Enos Wambu"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11452",title:"Cryopreservation - Applications and Challenges",subtitle:null,isOpenForSubmission:!0,hash:"a6c3fd4384ff7deeab32fc82722c60e0",slug:null,bookSignature:"Dr. Marian Quain",coverURL:"https://cdn.intechopen.com/books/images_new/11452.jpg",editedByType:null,editors:[{id:"300385",title:"Dr.",name:"Marian",surname:"Quain",slug:"marian-quain",fullName:"Marian Quain"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11453",title:"Biomimetics - Bridging the Gap",subtitle:null,isOpenForSubmission:!0,hash:"173e62fa4d7bf5508cec3bdd8e3cb32d",slug:null,bookSignature:"Prof. Ziyad S. Haidar",coverURL:"https://cdn.intechopen.com/books/images_new/11453.jpg",editedByType:null,editors:[{id:"222709",title:"Prof.",name:"Ziyad S.",surname:"Haidar",slug:"ziyad-s.-haidar",fullName:"Ziyad S. Haidar"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11507",title:"New Generation of Sustainable Smart Cities",subtitle:null,isOpenForSubmission:!0,hash:"dc693757b86ab8742367a38cda6cb622",slug:null,bookSignature:"Prof. Amjad Almusaed and Prof. Asaad Almssad",coverURL:"https://cdn.intechopen.com/books/images_new/11507.jpg",editedByType:null,editors:[{id:"446856",title:"Prof.",name:"Amjad",surname:"Almusaed",slug:"amjad-almusaed",fullName:"Amjad Almusaed"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11510",title:"New Trends in Electric Machines - Technology and Applications",subtitle:null,isOpenForSubmission:!0,hash:"f57b5e35a1bf18acd4fd0d41fe59f49c",slug:null,bookSignature:"Dr. Miguel Delgado Prieto, Dr. José Alfonso Antonino-Daviu and Dr. Roque A. Osornio-Rios",coverURL:"https://cdn.intechopen.com/books/images_new/11510.jpg",editedByType:null,editors:[{id:"234568",title:"Dr.",name:"Miguel",surname:"Delgado Prieto",slug:"miguel-delgado-prieto",fullName:"Miguel Delgado Prieto"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11513",title:"Gas Sensors",subtitle:null,isOpenForSubmission:!0,hash:"8eeb7ab232fa8d5c723b61e0da251857",slug:null,bookSignature:"Dr. Soumen Dhara and Dr. Gorachand Dutta",coverURL:"https://cdn.intechopen.com/books/images_new/11513.jpg",editedByType:null,editors:[{id:"196334",title:"Dr.",name:"Soumen",surname:"Dhara",slug:"soumen-dhara",fullName:"Soumen Dhara"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11514",title:"Vision Sensors - Recent Advances",subtitle:null,isOpenForSubmission:!0,hash:"6da8427ef3062c142b4e9650a5fed534",slug:null,bookSignature:"Dr. Francisco J. Gallegos-Funes",coverURL:"https://cdn.intechopen.com/books/images_new/11514.jpg",editedByType:null,editors:[{id:"2868",title:"Dr.",name:"Francisco",surname:"Gallegos-Funes",slug:"francisco-gallegos-funes",fullName:"Francisco Gallegos-Funes"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11515",title:"Light-Emitting Diodes - New Perspectives",subtitle:null,isOpenForSubmission:!0,hash:"08a7e9ae6b64e49a2118515e285b78da",slug:null,bookSignature:"Dr. Chandra Shakher Pathak and Mr. Uday Dadwal",coverURL:"https://cdn.intechopen.com/books/images_new/11515.jpg",editedByType:null,editors:[{id:"318029",title:"Dr.",name:"Chandra Shakher",surname:"Pathak",slug:"chandra-shakher-pathak",fullName:"Chandra Shakher Pathak"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11518",title:"The Acoustics of Materials - New Approaches",subtitle:null,isOpenForSubmission:!0,hash:"769f942393275479acca64e4f4fea958",slug:null,bookSignature:"Dr. Bankole Kolawole Fasanya and Dr. Sridhar Krishnamurti",coverURL:"https://cdn.intechopen.com/books/images_new/11518.jpg",editedByType:null,editors:[{id:"214494",title:"Dr.",name:"Bankole",surname:"Fasanya",slug:"bankole-fasanya",fullName:"Bankole Fasanya"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11520",title:"Direct Torque Control",subtitle:null,isOpenForSubmission:!0,hash:"6504dee75dbbfd7792308293a8f1a27f",slug:null,bookSignature:"Prof. Moulay Tahar Lamchich",coverURL:"https://cdn.intechopen.com/books/images_new/11520.jpg",editedByType:null,editors:[{id:"21932",title:"Prof.",name:"Moulay Tahar",surname:"Lamchich",slug:"moulay-tahar-lamchich",fullName:"Moulay Tahar Lamchich"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11521",title:"Internal Combustion Engines - Recent Advances",subtitle:null,isOpenForSubmission:!0,hash:"99cc881bcb3efe05085f2728ccbeab6b",slug:null,bookSignature:"Prof. Akaehomen Akii Ibhadode",coverURL:"https://cdn.intechopen.com/books/images_new/11521.jpg",editedByType:null,editors:[{id:"253342",title:"Prof.",name:"Akaehomen",surname:"Ibhadode",slug:"akaehomen-ibhadode",fullName:"Akaehomen Ibhadode"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11526",title:"Mass Production in the Industry 4.0 Era",subtitle:null,isOpenForSubmission:!0,hash:"082678c3d4e60a3ac282f3f2309379d4",slug:null,bookSignature:"Dr. Tamás Bányai",coverURL:"https://cdn.intechopen.com/books/images_new/11526.jpg",editedByType:null,editors:[{id:"201248",title:"Dr.",name:"Tamás",surname:"Bányai",slug:"tamas-banyai",fullName:"Tamás Bányai"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:36},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:11},{group:"topic",caption:"Business, Management and Economics",value:7,count:7},{group:"topic",caption:"Chemistry",value:8,count:22},{group:"topic",caption:"Computer and Information Science",value:9,count:23},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:15},{group:"topic",caption:"Engineering",value:11,count:60},{group:"topic",caption:"Environmental Sciences",value:12,count:9},{group:"topic",caption:"Immunology and Microbiology",value:13,count:14},{group:"topic",caption:"Materials Science",value:14,count:23},{group:"topic",caption:"Mathematics",value:15,count:11},{group:"topic",caption:"Medicine",value:16,count:106},{group:"topic",caption:"Nanotechnology and Nanomaterials",value:17,count:6},{group:"topic",caption:"Neuroscience",value:18,count:3},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:9},{group:"topic",caption:"Physics",value:20,count:9},{group:"topic",caption:"Psychology",value:21,count:9},{group:"topic",caption:"Robotics",value:22,count:2},{group:"topic",caption:"Social Sciences",value:23,count:9},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:3}],offset:12,limit:12,total:85},popularBooks:{featuredBooks:[{type:"book",id:"10858",title:"MOOC (Massive Open Online Courses)",subtitle:null,isOpenForSubmission:!1,hash:"d32f86793bc72dde32532f509b1ec5b0",slug:"mooc-massive-open-online-courses-",bookSignature:"Dragan Cvetković",coverURL:"https://cdn.intechopen.com/books/images_new/10858.jpg",editors:[{id:"101330",title:"Dr.",name:"Dragan",middleName:"Mladen",surname:"Cvetković",slug:"dragan-cvetkovic",fullName:"Dragan Cvetković"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10195",title:"Serotonin and the CNS",subtitle:"New Developments in Pharmacology and Therapeutics",isOpenForSubmission:!1,hash:"7ed9d96da98233a885bd2869a8056c36",slug:"serotonin-and-the-cns-new-developments-in-pharmacology-and-therapeutics",bookSignature:"Berend Olivier",coverURL:"https://cdn.intechopen.com/books/images_new/10195.jpg",editors:[{id:"71579",title:"Prof.",name:"Berend",middleName:null,surname:"Olivier",slug:"berend-olivier",fullName:"Berend Olivier"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10755",title:"Corporate Governance",subtitle:"Recent Advances and Perspectives",isOpenForSubmission:!1,hash:"ffe06d1d5c4bf0fc2e63511825fe1257",slug:"corporate-governance-recent-advances-and-perspectives",bookSignature:"Okechukwu Lawrence Emeagwali and Feyza Bhatti",coverURL:"https://cdn.intechopen.com/books/images_new/10755.jpg",editors:[{id:"196317",title:"Associate Prof.",name:"Okechukwu Lawrence",middleName:null,surname:"Emeagwali",slug:"okechukwu-lawrence-emeagwali",fullName:"Okechukwu Lawrence Emeagwali"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"11120",title:"Environmental Impact and Remediation of Heavy Metals",subtitle:null,isOpenForSubmission:!1,hash:"9e77514288e7394f1e6cd13481af3509",slug:"environmental-impact-and-remediation-of-heavy-metals",bookSignature:"Hosam M. Saleh and Amal I. Hassan",coverURL:"https://cdn.intechopen.com/books/images_new/11120.jpg",editors:[{id:"144691",title:"Prof.",name:"Hosam M.",middleName:null,surname:"Saleh",slug:"hosam-m.-saleh",fullName:"Hosam M. Saleh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10901",title:"Grapes and Wine",subtitle:null,isOpenForSubmission:!1,hash:"5d7f2aa74874444bc6986e613ccebd7c",slug:"grapes-and-wine",bookSignature:"Antonio Morata, Iris Loira and Carmen González",coverURL:"https://cdn.intechopen.com/books/images_new/10901.jpg",editors:[{id:"180952",title:"Prof.",name:"Antonio",middleName:null,surname:"Morata",slug:"antonio-morata",fullName:"Antonio Morata"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"11080",title:"Engineering Principles",subtitle:"Welding and Residual Stresses",isOpenForSubmission:!1,hash:"6c07a13a113bce94174b40096f30fb5e",slug:"engineering-principles-welding-and-residual-stresses",bookSignature:"Kavian Omar Cooke and Ronaldo Câmara Cozza",coverURL:"https://cdn.intechopen.com/books/images_new/11080.jpg",editors:[{id:"138778",title:"Dr.",name:"Kavian",middleName:"Omar",surname:"Cooke",slug:"kavian-cooke",fullName:"Kavian Cooke"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"11332",title:"Essential Oils",subtitle:"Advances in Extractions and Biological Applications",isOpenForSubmission:!1,hash:"742e6cae3a35686f975edc8d7f9afa94",slug:"essential-oils-advances-in-extractions-and-biological-applications",bookSignature:"Mozaniel Santana de Oliveira and Eloisa Helena de Aguiar Andrade",coverURL:"https://cdn.intechopen.com/books/images_new/11332.jpg",editors:[{id:"195290",title:"Ph.D.",name:"Mozaniel",middleName:null,surname:"Santana De Oliveira",slug:"mozaniel-santana-de-oliveira",fullName:"Mozaniel Santana De Oliveira"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"11029",title:"Hepatitis B",subtitle:null,isOpenForSubmission:!1,hash:"609701f502efc3538c112ff47a2c2119",slug:"hepatitis-b",bookSignature:"Luis Rodrigo",coverURL:"https://cdn.intechopen.com/books/images_new/11029.jpg",editors:[{id:"73208",title:"Prof.",name:"Luis",middleName:null,surname:"Rodrigo",slug:"luis-rodrigo",fullName:"Luis Rodrigo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9537",title:"Human Rights in the Contemporary World",subtitle:null,isOpenForSubmission:!1,hash:"54f05b93812fd434f3962956d6413a6b",slug:"human-rights-in-the-contemporary-world",bookSignature:"Trudy Corrigan",coverURL:"https://cdn.intechopen.com/books/images_new/9537.jpg",editors:[{id:"197557",title:"Dr.",name:"Trudy",middleName:null,surname:"Corrigan",slug:"trudy-corrigan",fullName:"Trudy Corrigan"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"11371",title:"Cerebral Circulation",subtitle:"Updates on Models, Diagnostics and Treatments of Related Diseases",isOpenForSubmission:!1,hash:"e2d3335445d2852d0b906bb9750e939f",slug:"cerebral-circulation-updates-on-models-diagnostics-and-treatments-of-related-diseases",bookSignature:"Alba Scerrati, Luca Ricciardi and Flavia Dones",coverURL:"https://cdn.intechopen.com/books/images_new/11371.jpg",editors:[{id:"182614",title:"Dr.",name:"Alba",middleName:null,surname:"Scerrati",slug:"alba-scerrati",fullName:"Alba Scerrati"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"11012",title:"Radiopharmaceuticals",subtitle:"Current Research for Better Diagnosis and Therapy",isOpenForSubmission:!1,hash:"f9046d6f96148b285e776f384991120d",slug:"radiopharmaceuticals-current-research-for-better-diagnosis-and-therapy",bookSignature:"Farid A. Badria",coverURL:"https://cdn.intechopen.com/books/images_new/11012.jpg",editors:[{id:"41865",title:"Prof.",name:"Farid A.",middleName:null,surname:"Badria",slug:"farid-a.-badria",fullName:"Farid A. Badria"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9974",title:"E-Learning and Digital Education in the Twenty-First Century",subtitle:null,isOpenForSubmission:!1,hash:"88b58d66e975df20425fc1dfd22d53aa",slug:"e-learning-and-digital-education-in-the-twenty-first-century",bookSignature:"M. Mahruf C. Shohel",coverURL:"https://cdn.intechopen.com/books/images_new/9974.jpg",editors:[{id:"94099",title:"Dr.",name:"M. Mahruf C.",middleName:null,surname:"Shohel",slug:"m.-mahruf-c.-shohel",fullName:"M. Mahruf C. Shohel"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:4553},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"10858",title:"MOOC (Massive Open Online Courses)",subtitle:null,isOpenForSubmission:!1,hash:"d32f86793bc72dde32532f509b1ec5b0",slug:"mooc-massive-open-online-courses-",bookSignature:"Dragan Cvetković",coverURL:"https://cdn.intechopen.com/books/images_new/10858.jpg",publishedDate:"June 23rd 2022",numberOfDownloads:1677,editors:[{id:"101330",title:"Dr.",name:"Dragan",middleName:"Mladen",surname:"Cvetković",slug:"dragan-cvetkovic",fullName:"Dragan Cvetković"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10195",title:"Serotonin and the CNS",subtitle:"New Developments in Pharmacology and Therapeutics",isOpenForSubmission:!1,hash:"7ed9d96da98233a885bd2869a8056c36",slug:"serotonin-and-the-cns-new-developments-in-pharmacology-and-therapeutics",bookSignature:"Berend Olivier",coverURL:"https://cdn.intechopen.com/books/images_new/10195.jpg",publishedDate:"June 23rd 2022",numberOfDownloads:1337,editors:[{id:"71579",title:"Prof.",name:"Berend",middleName:null,surname:"Olivier",slug:"berend-olivier",fullName:"Berend Olivier"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10755",title:"Corporate Governance",subtitle:"Recent Advances and Perspectives",isOpenForSubmission:!1,hash:"ffe06d1d5c4bf0fc2e63511825fe1257",slug:"corporate-governance-recent-advances-and-perspectives",bookSignature:"Okechukwu Lawrence Emeagwali and Feyza Bhatti",coverURL:"https://cdn.intechopen.com/books/images_new/10755.jpg",publishedDate:"June 23rd 2022",numberOfDownloads:1309,editors:[{id:"196317",title:"Associate Prof.",name:"Okechukwu Lawrence",middleName:null,surname:"Emeagwali",slug:"okechukwu-lawrence-emeagwali",fullName:"Okechukwu Lawrence Emeagwali"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"11120",title:"Environmental Impact and Remediation of Heavy Metals",subtitle:null,isOpenForSubmission:!1,hash:"9e77514288e7394f1e6cd13481af3509",slug:"environmental-impact-and-remediation-of-heavy-metals",bookSignature:"Hosam M. Saleh and Amal I. Hassan",coverURL:"https://cdn.intechopen.com/books/images_new/11120.jpg",publishedDate:"June 23rd 2022",numberOfDownloads:847,editors:[{id:"144691",title:"Prof.",name:"Hosam M.",middleName:null,surname:"Saleh",slug:"hosam-m.-saleh",fullName:"Hosam M. Saleh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10901",title:"Grapes and Wine",subtitle:null,isOpenForSubmission:!1,hash:"5d7f2aa74874444bc6986e613ccebd7c",slug:"grapes-and-wine",bookSignature:"Antonio Morata, Iris Loira and Carmen González",coverURL:"https://cdn.intechopen.com/books/images_new/10901.jpg",publishedDate:"June 15th 2022",numberOfDownloads:2273,editors:[{id:"180952",title:"Prof.",name:"Antonio",middleName:null,surname:"Morata",slug:"antonio-morata",fullName:"Antonio Morata"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"11080",title:"Engineering Principles",subtitle:"Welding and Residual Stresses",isOpenForSubmission:!1,hash:"6c07a13a113bce94174b40096f30fb5e",slug:"engineering-principles-welding-and-residual-stresses",bookSignature:"Kavian Omar Cooke and Ronaldo Câmara Cozza",coverURL:"https://cdn.intechopen.com/books/images_new/11080.jpg",publishedDate:"June 23rd 2022",numberOfDownloads:591,editors:[{id:"138778",title:"Dr.",name:"Kavian",middleName:"Omar",surname:"Cooke",slug:"kavian-cooke",fullName:"Kavian Cooke"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"11332",title:"Essential Oils",subtitle:"Advances in Extractions and Biological Applications",isOpenForSubmission:!1,hash:"742e6cae3a35686f975edc8d7f9afa94",slug:"essential-oils-advances-in-extractions-and-biological-applications",bookSignature:"Mozaniel Santana de Oliveira and Eloisa Helena de Aguiar Andrade",coverURL:"https://cdn.intechopen.com/books/images_new/11332.jpg",publishedDate:"June 23rd 2022",numberOfDownloads:515,editors:[{id:"195290",title:"Ph.D.",name:"Mozaniel",middleName:null,surname:"Santana De Oliveira",slug:"mozaniel-santana-de-oliveira",fullName:"Mozaniel Santana De Oliveira"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"11029",title:"Hepatitis B",subtitle:null,isOpenForSubmission:!1,hash:"609701f502efc3538c112ff47a2c2119",slug:"hepatitis-b",bookSignature:"Luis Rodrigo",coverURL:"https://cdn.intechopen.com/books/images_new/11029.jpg",publishedDate:"June 23rd 2022",numberOfDownloads:413,editors:[{id:"73208",title:"Prof.",name:"Luis",middleName:null,surname:"Rodrigo",slug:"luis-rodrigo",fullName:"Luis Rodrigo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9537",title:"Human Rights in the Contemporary World",subtitle:null,isOpenForSubmission:!1,hash:"54f05b93812fd434f3962956d6413a6b",slug:"human-rights-in-the-contemporary-world",bookSignature:"Trudy Corrigan",coverURL:"https://cdn.intechopen.com/books/images_new/9537.jpg",publishedDate:"June 8th 2022",numberOfDownloads:2194,editors:[{id:"197557",title:"Dr.",name:"Trudy",middleName:null,surname:"Corrigan",slug:"trudy-corrigan",fullName:"Trudy Corrigan"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"11371",title:"Cerebral Circulation",subtitle:"Updates on Models, Diagnostics and Treatments of Related Diseases",isOpenForSubmission:!1,hash:"e2d3335445d2852d0b906bb9750e939f",slug:"cerebral-circulation-updates-on-models-diagnostics-and-treatments-of-related-diseases",bookSignature:"Alba Scerrati, Luca Ricciardi and Flavia Dones",coverURL:"https://cdn.intechopen.com/books/images_new/11371.jpg",publishedDate:"June 23rd 2022",numberOfDownloads:341,editors:[{id:"182614",title:"Dr.",name:"Alba",middleName:null,surname:"Scerrati",slug:"alba-scerrati",fullName:"Alba Scerrati"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"11042",title:"Complementary Therapies",subtitle:null,isOpenForSubmission:!1,hash:"9eb32ccbef95289a133a76e5808a525b",slug:"complementary-therapies",bookSignature:"Mario Bernardo-Filho, Redha Taiar, Danúbia da Cunha de Sá-Caputo and Adérito Seixas",coverURL:"https://cdn.intechopen.com/books/images_new/11042.jpg",editedByType:"Edited by",publishedDate:"July 6th 2022",editors:[{id:"157376",title:"Prof.",name:"Mario",middleName:null,surname:"Bernardo-Filho",slug:"mario-bernardo-filho",fullName:"Mario Bernardo-Filho"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10037",title:"Thermoelectricity",subtitle:"Recent Advances, New Perspectives and Applications",isOpenForSubmission:!1,hash:"ad1d3f637564a29cf1636759f5401994",slug:"thermoelectricity-recent-advances-new-perspectives-and-applications",bookSignature:"Guangzhao Qin",coverURL:"https://cdn.intechopen.com/books/images_new/10037.jpg",editedByType:"Edited by",publishedDate:"July 6th 2022",editors:[{id:"188870",title:"Mr.",name:"Guangzhao",middleName:null,surname:"Qin",slug:"guangzhao-qin",fullName:"Guangzhao Qin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11357",title:"Sustainable Crop Production",subtitle:"Recent Advances",isOpenForSubmission:!1,hash:"ee41e09e4ad6a336ca9f0e5462da3904",slug:"sustainable-crop-production-recent-advances",bookSignature:"Vijay Singh Meena, Mahipal Choudhary, Ram Prakash Yadav and Sunita Kumari Meena",coverURL:"https://cdn.intechopen.com/books/images_new/11357.jpg",editedByType:"Edited by",publishedDate:"July 6th 2022",editors:[{id:"420235",title:"Dr.",name:"Vijay",middleName:null,surname:"Meena",slug:"vijay-meena",fullName:"Vijay Meena"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10863",title:"Cardiac Rhythm Management",subtitle:"Pacing, Ablation, Devices",isOpenForSubmission:!1,hash:"a064ec49b85ebfc60585c9c3690af53a",slug:"cardiac-rhythm-management-pacing-ablation-devices",bookSignature:"Mart Min and Gabriel Cismaru",coverURL:"https://cdn.intechopen.com/books/images_new/10863.jpg",editedByType:"Edited by",publishedDate:"July 6th 2022",editors:[{id:"62780",title:"Prof.",name:"Mart",middleName:null,surname:"Min",slug:"mart-min",fullName:"Mart Min"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10874",title:"Insights on Antimicrobial Peptides",subtitle:null,isOpenForSubmission:!1,hash:"23ca26025e87356a7c2ffac365f73a22",slug:"insights-on-antimicrobial-peptides",bookSignature:"Shymaa Enany, Jorge Masso-Silva and Anna Savitskaya",coverURL:"https://cdn.intechopen.com/books/images_new/10874.jpg",editedByType:"Edited by",publishedDate:"July 6th 2022",editors:[{id:"81926",title:"Dr.",name:"Shymaa",middleName:null,surname:"Enany",slug:"shymaa-enany",fullName:"Shymaa Enany"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11137",title:"Mineralogy",subtitle:null,isOpenForSubmission:!1,hash:"e0e4727c9f1f9b34d788f0dc70278f2b",slug:"mineralogy",bookSignature:"Miloš René",coverURL:"https://cdn.intechopen.com/books/images_new/11137.jpg",editedByType:"Edited by",publishedDate:"July 6th 2022",editors:[{id:"142108",title:"Dr.",name:"Miloš",middleName:null,surname:"René",slug:"milos-rene",fullName:"Miloš René"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10882",title:"Smart Drug Delivery",subtitle:null,isOpenForSubmission:!1,hash:"70c3ce4256324b3c58db970d446ddac4",slug:"smart-drug-delivery",bookSignature:"Usama Ahmad, Md. Faheem Haider and Juber Akhtar",coverURL:"https://cdn.intechopen.com/books/images_new/10882.jpg",editedByType:"Edited by",publishedDate:"July 6th 2022",editors:[{id:"255360",title:"Dr.",name:"Usama",middleName:null,surname:"Ahmad",slug:"usama-ahmad",fullName:"Usama Ahmad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10885",title:"Snake Venom and Ecology",subtitle:null,isOpenForSubmission:!1,hash:"cc4503ed9e56a7bcd9f2ca82b0c880a8",slug:"snake-venom-and-ecology",bookSignature:"Mohammad Manjur Shah, Umar Sharif, Tijjani Rufai Buhari and Tijjani Sabiu Imam",coverURL:"https://cdn.intechopen.com/books/images_new/10885.jpg",editedByType:"Edited by",publishedDate:"July 6th 2022",editors:[{id:"94128",title:"Dr.",name:"Mohammad Manjur",middleName:null,surname:"Shah",slug:"mohammad-manjur-shah",fullName:"Mohammad Manjur Shah"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10381",title:"Electrocatalysis and Electrocatalysts for a Cleaner Environment",subtitle:"Fundamentals and Applications",isOpenForSubmission:!1,hash:"9dbafb0b297cf5cbdb220707e022a228",slug:"electrocatalysis-and-electrocatalysts-for-a-cleaner-environment-fundamentals-and-applications",bookSignature:"Lindiwe Eudora Khotseng",coverURL:"https://cdn.intechopen.com/books/images_new/10381.jpg",editedByType:"Edited by",publishedDate:"July 6th 2022",editors:[{id:"236596",title:"Dr.",name:"Lindiwe Eudora",middleName:null,surname:"Khotseng",slug:"lindiwe-eudora-khotseng",fullName:"Lindiwe Eudora Khotseng"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10900",title:"Prunus",subtitle:"Recent Advances",isOpenForSubmission:!1,hash:"9261926500acb26c4ae5a29eee78f0db",slug:"prunus-recent-advances",bookSignature:"Ayzin B. Küden and Ali Küden",coverURL:"https://cdn.intechopen.com/books/images_new/10900.jpg",editedByType:"Edited by",publishedDate:"July 6th 2022",editors:[{id:"200365",title:"Prof.",name:"Ayzin B.",middleName:"B.",surname:"Küden",slug:"ayzin-b.-kuden",fullName:"Ayzin B. Küden"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"75",title:"Mathematical Economics",slug:"mathematical-economics",parent:{id:"7",title:"Business, Management and Economics",slug:"business-management-and-economics"},numberOfBooks:2,numberOfSeries:0,numberOfAuthorsAndEditors:45,numberOfWosCitations:29,numberOfCrossrefCitations:18,numberOfDimensionsCitations:30,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicId:"75",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"6756",title:"Game Theory",subtitle:"Applications in Logistics and Economy",isOpenForSubmission:!1,hash:"1505777b52bab72af52d9aa2fd7268b4",slug:"game-theory-applications-in-logistics-and-economy",bookSignature:"Danijela Tuljak-Suban",coverURL:"https://cdn.intechopen.com/books/images_new/6756.jpg",editedByType:"Edited by",editors:[{id:"172905",title:"Dr.",name:"Danijela",middleName:null,surname:"Tuljak-Suban",slug:"danijela-tuljak-suban",fullName:"Danijela Tuljak-Suban"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2169",title:"Game Theory Relaunched",subtitle:null,isOpenForSubmission:!1,hash:"cb5f736047f76c11d171761ff8b7443f",slug:"game-theory-relaunched",bookSignature:"Hardy Hanappi",coverURL:"https://cdn.intechopen.com/books/images_new/2169.jpg",editedByType:"Edited by",editors:[{id:"145817",title:"Prof.",name:"Hardy",middleName:null,surname:"Hanappi",slug:"hardy-hanappi",fullName:"Hardy Hanappi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:2,seriesByTopicCollection:[],seriesByTopicTotal:0,mostCitedChapters:[{id:"43942",doi:"10.5772/54380",title:"A Game Theoretic Analysis of Price-QoS Market Share in Presence of Adversarial Service Providers",slug:"a-game-theoretic-analysis-of-price-qos-market-share-in-presence-of-adversarial-service-providers",totalDownloads:2405,totalCrossrefCites:5,totalDimensionsCites:7,abstract:null,book:{id:"2169",slug:"game-theory-relaunched",title:"Game Theory Relaunched",fullTitle:"Game Theory Relaunched"},signatures:"Mohamed Baslam, Rachid El-Azouzi, Essaid Sabir, Loubna Echabbi and El-Houssine Bouyakhf",authors:[{id:"124824",title:"Prof.",name:"Rachid",middleName:null,surname:"El-Azouzi",slug:"rachid-el-azouzi",fullName:"Rachid El-Azouzi"},{id:"149048",title:"Dr.",name:"Baslam",middleName:null,surname:"Mohamed",slug:"baslam-mohamed",fullName:"Baslam Mohamed"},{id:"149050",title:"Dr.",name:"Essaid",middleName:null,surname:"Sabir",slug:"essaid-sabir",fullName:"Essaid Sabir"},{id:"149051",title:"Dr.",name:"Echabbi",middleName:null,surname:"Loubna",slug:"echabbi-loubna",fullName:"Echabbi Loubna"},{id:"149052",title:"Prof.",name:"Bouyakhf",middleName:null,surname:"El-Houssine",slug:"bouyakhf-el-houssine",fullName:"Bouyakhf El-Houssine"}]},{id:"43917",doi:"10.5772/54677",title:"Nash Equilibrium Strategies in Fuzzy Games",slug:"nash-equilibrium-strategies-in-fuzzy-games",totalDownloads:3841,totalCrossrefCites:2,totalDimensionsCites:6,abstract:null,book:{id:"2169",slug:"game-theory-relaunched",title:"Game Theory Relaunched",fullTitle:"Game Theory Relaunched"},signatures:"Alireza Chakeri, Nasser Sadati and Guy A. Dumont",authors:[{id:"17139",title:"Prof.",name:"Guy A.",middleName:null,surname:"Dumont",slug:"guy-a.-dumont",fullName:"Guy A. Dumont"},{id:"145501",title:"Ph.D. Student",name:"Alireza",middleName:null,surname:"Chakeri",slug:"alireza-chakeri",fullName:"Alireza Chakeri"},{id:"148888",title:"Dr.",name:"Nasser",middleName:null,surname:"Sadati",slug:"nasser-sadati",fullName:"Nasser Sadati"}]},{id:"43916",doi:"10.5772/54425",title:"A Tale of Two Ports: Extending the Bertrand Model Along the Needs of a Case Study",slug:"a-tale-of-two-ports-extending-the-bertrand-model-along-the-needs-of-a-case-study",totalDownloads:3598,totalCrossrefCites:3,totalDimensionsCites:3,abstract:null,book:{id:"2169",slug:"game-theory-relaunched",title:"Game Theory Relaunched",fullTitle:"Game Theory Relaunched"},signatures:"Naima Saeed and Odd I. Larsen",authors:[{id:"145353",title:"Dr.",name:"Naima",middleName:null,surname:"Saeed",slug:"naima-saeed",fullName:"Naima Saeed"},{id:"145425",title:"Prof.",name:"Odd",middleName:null,surname:"Larsen",slug:"odd-larsen",fullName:"Odd Larsen"}]},{id:"43940",doi:"10.5772/54377",title:"Models of Paradoxical Coincident Cost Degradation in Noncooperative Networks",slug:"models-of-paradoxical-coincident-cost-degradation-in-noncooperative-networks",totalDownloads:1742,totalCrossrefCites:1,totalDimensionsCites:2,abstract:null,book:{id:"2169",slug:"game-theory-relaunched",title:"Game Theory Relaunched",fullTitle:"Game Theory Relaunched"},signatures:"Hisao Kameda",authors:[{id:"12714",title:"Prof.",name:"Hisao",middleName:null,surname:"Kameda",slug:"hisao-kameda",fullName:"Hisao Kameda"}]},{id:"43915",doi:"10.5772/56106",title:"The Neumann-Morgenstern Project – Game Theory as a Formal Language for the Social Sciences",slug:"the-neumann-morgenstern-project-game-theory-as-a-formal-language-for-the-social-sciences",totalDownloads:5393,totalCrossrefCites:1,totalDimensionsCites:2,abstract:null,book:{id:"2169",slug:"game-theory-relaunched",title:"Game Theory Relaunched",fullTitle:"Game Theory Relaunched"},signatures:"Hardy Hanappi",authors:[{id:"145817",title:"Prof.",name:"Hardy",middleName:null,surname:"Hanappi",slug:"hardy-hanappi",fullName:"Hardy Hanappi"}]}],mostDownloadedChaptersLast30Days:[{id:"43920",title:"Models for Highway Cost Allocation",slug:"models-for-highway-cost-allocation",totalDownloads:3474,totalCrossrefCites:2,totalDimensionsCites:1,abstract:null,book:{id:"2169",slug:"game-theory-relaunched",title:"Game Theory Relaunched",fullTitle:"Game Theory Relaunched"},signatures:"Alberto Garcia-Diaz and Dong-Ju Lee",authors:[{id:"146465",title:"Dr.",name:"Alberto",middleName:null,surname:"Garcia-Diaz",slug:"alberto-garcia-diaz",fullName:"Alberto Garcia-Diaz"},{id:"147887",title:"Prof.",name:"DongJu",middleName:null,surname:"Lee",slug:"dongju-lee",fullName:"DongJu Lee"}]},{id:"60490",title:"Stochastic Leader-Follower Differential Game with Asymmetric Information",slug:"stochastic-leader-follower-differential-game-with-asymmetric-information",totalDownloads:870,totalCrossrefCites:0,totalDimensionsCites:0,abstract:"In this chapter, we discuss a leader-follower (also called Stackelberg) stochastic differential game with asymmetric information. Here the word “asymmetric” means that the available information of the follower is some sub-\n\nσ\n\n-algebra of that available to the leader, though they play as different roles in the classical literatures. Stackelberg equilibrium is represented by the stochastic versions of Pontryagin’s maximum principle and verification theorem with partial information. A linear-quadratic (LQ) leader-follower stochastic differential game with asymmetric information is studied as applications. If some system of Riccati equations is solvable, the Stackelberg equilibrium admits a state feedback representation.",book:{id:"6756",slug:"game-theory-applications-in-logistics-and-economy",title:"Game Theory",fullTitle:"Game Theory - Applications in Logistics and Economy"},signatures:"Jingtao Shi",authors:[{id:"147959",title:"Dr.",name:"Jingtao",middleName:null,surname:"Shi",slug:"jingtao-shi",fullName:"Jingtao Shi"}]},{id:"62516",title:"The Game Theory: Applications in the Wireless Networks",slug:"the-game-theory-applications-in-the-wireless-networks",totalDownloads:1444,totalCrossrefCites:2,totalDimensionsCites:2,abstract:"Recent years have witnessed a lot of applications in the computer science, especially in the area of the wireless networks. The applications can be divided into the following two main categories: applications in the network performance and those in the energy efficiency. The game theory is widely used to regulate the behavior of the users; therefore, the cooperation among the nodes can be achieved and the network performance can be improved when the game theory is utilized. On the other hand, the game theory is also adopted to control the media access control protocol or routing protocol; therefore, the energy exhaust owing to the data collision and long route can be reduced and the energy efficiency can be improved greatly. In this chapter, the applications in the network performance and the energy efficiency are reviewed. The state of the art in the applications of the game theory in wireless networks is pointed out. Finally, the future research direction of the game theory in the energy harvesting wireless sensor network is presented.",book:{id:"6756",slug:"game-theory-applications-in-logistics-and-economy",title:"Game Theory",fullTitle:"Game Theory - Applications in Logistics and Economy"},signatures:"Deyu Lin, Quan Wang and Pengfei Yang",authors:[{id:"258432",title:"Dr.",name:"Deyu",middleName:null,surname:"Lin",slug:"deyu-lin",fullName:"Deyu Lin"},{id:"259049",title:"Prof.",name:"Quan",middleName:null,surname:"Wang",slug:"quan-wang",fullName:"Quan Wang"},{id:"261098",title:"Dr.",name:"Pengfei",middleName:null,surname:"Yang",slug:"pengfei-yang",fullName:"Pengfei Yang"}]},{id:"63373",title:"Infinite Supermodularity and Preferences",slug:"infinite-supermodularity-and-preferences",totalDownloads:967,totalCrossrefCites:0,totalDimensionsCites:0,abstract:"This chapter studies the ordinal content of supermodularity on lattices. This chapter is a generalization of the famous study of binary relations over finite Boolean algebras obtained by Wong, Yao and Lingras. We study the implications of various types of supermodularity for preferences over finite lattices. We prove that preferences on a finite lattice merely respecting the lattice order cannot disentangle these usual economic assumptions of supermodularity and infinite supermodularity. More precisely, the existence of a supermodular representation is equivalent to the existence of an infinitely supermodular representation. In addition, the strict increasingness of a complete preorder on a finite lattice is equivalent to the existence of a strictly increasing and infinitely supermodular representation. For wide classes of binary relations, the ordinal contents of quasisupermodularity, supermodularity and infinite supermodularity are exactly the same. In the end, we extend our results from finite lattices to infinite lattices.",book:{id:"6756",slug:"game-theory-applications-in-logistics-and-economy",title:"Game Theory",fullTitle:"Game Theory - Applications in Logistics and Economy"},signatures:"Alain Chateauneuf, Vassili Vergopoulos and Jianbo Zhang",authors:[{id:"248905",title:"Prof.",name:"Jianbo",middleName:null,surname:"Zhang",slug:"jianbo-zhang",fullName:"Jianbo Zhang"},{id:"248908",title:"Prof.",name:"Alain",middleName:null,surname:"Chateauneuf",slug:"alain-chateauneuf",fullName:"Alain Chateauneuf"},{id:"248910",title:"Dr.",name:"Vassili",middleName:null,surname:"Vergopoulos",slug:"vassili-vergopoulos",fullName:"Vassili Vergopoulos"}]},{id:"60809",title:"Game Theory Application in Smart Energy Logistics and Economy",slug:"game-theory-application-in-smart-energy-logistics-and-economy",totalDownloads:1012,totalCrossrefCites:0,totalDimensionsCites:0,abstract:"In many parts of the world, energy sectors are transformed from conventional to the smart deregulated market structures. In such smart deregulated market environment, cooperative game theory can play a vital role for analyzing various smart deregulated market problems. As an optimization tool, cooperative game theory is very useful in smart energy logistics and economy analysis problem. The economy associated with smart deregulated structure can be better optimized and allocated with the help of cooperative game theory. Initially, due to regulated structure, there is no cooperation between different entities of energy sector. But after new market structure, all the entities are free to take their own decisions as an independent entity. Transmission open access of energy logistics is also comes into the picture, as all the generators and demands have the same right to access the transmission system. In this market situation, multiple utilities are using the same energy logistic network. This situation can be formulated as a cooperative game in which generators and demands are represented by players. This chapter deals with energy logistic cost allocation problems for a smart deregulated energy market. It is cooperative in nature as all the agents are using the same energy logistic network.",book:{id:"6756",slug:"game-theory-applications-in-logistics-and-economy",title:"Game Theory",fullTitle:"Game Theory - Applications in Logistics and Economy"},signatures:"Baseem Khan",authors:[{id:"240063",title:"Dr.",name:"Baseem",middleName:null,surname:"Khan",slug:"baseem-khan",fullName:"Baseem Khan"}]}],onlineFirstChaptersFilter:{topicId:"75",limit:6,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},subscriptionForm:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[],offset:0,limit:8,total:null},allSeries:{pteSeriesList:[{id:"14",title:"Artificial Intelligence",numberOfPublishedBooks:9,numberOfPublishedChapters:90,numberOfOpenTopics:6,numberOfUpcomingTopics:0,issn:"2633-1403",doi:"10.5772/intechopen.79920",isOpenForSubmission:!0},{id:"7",title:"Biomedical Engineering",numberOfPublishedBooks:12,numberOfPublishedChapters:104,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2631-5343",doi:"10.5772/intechopen.71985",isOpenForSubmission:!0}],lsSeriesList:[{id:"11",title:"Biochemistry",numberOfPublishedBooks:32,numberOfPublishedChapters:320,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2632-0983",doi:"10.5772/intechopen.72877",isOpenForSubmission:!0},{id:"25",title:"Environmental Sciences",numberOfPublishedBooks:1,numberOfPublishedChapters:12,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2754-6713",doi:"10.5772/intechopen.100362",isOpenForSubmission:!0},{id:"10",title:"Physiology",numberOfPublishedBooks:11,numberOfPublishedChapters:141,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2631-8261",doi:"10.5772/intechopen.72796",isOpenForSubmission:!0}],hsSeriesList:[{id:"3",title:"Dentistry",numberOfPublishedBooks:8,numberOfPublishedChapters:133,numberOfOpenTopics:2,numberOfUpcomingTopics:0,issn:"2631-6218",doi:"10.5772/intechopen.71199",isOpenForSubmission:!0},{id:"6",title:"Infectious Diseases",numberOfPublishedBooks:13,numberOfPublishedChapters:113,numberOfOpenTopics:3,numberOfUpcomingTopics:1,issn:"2631-6188",doi:"10.5772/intechopen.71852",isOpenForSubmission:!0},{id:"13",title:"Veterinary Medicine and Science",numberOfPublishedBooks:11,numberOfPublishedChapters:107,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2632-0517",doi:"10.5772/intechopen.73681",isOpenForSubmission:!0}],sshSeriesList:[{id:"22",title:"Business, Management and Economics",numberOfPublishedBooks:1,numberOfPublishedChapters:19,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2753-894X",doi:"10.5772/intechopen.100359",isOpenForSubmission:!0},{id:"23",title:"Education and Human Development",numberOfPublishedBooks:0,numberOfPublishedChapters:5,numberOfOpenTopics:1,numberOfUpcomingTopics:1,issn:null,doi:"10.5772/intechopen.100360",isOpenForSubmission:!0},{id:"24",title:"Sustainable Development",numberOfPublishedBooks:0,numberOfPublishedChapters:17,numberOfOpenTopics:5,numberOfUpcomingTopics:0,issn:null,doi:"10.5772/intechopen.100361",isOpenForSubmission:!0}],testimonialsList:[{id:"13",text:"The collaboration with and support of the technical staff of IntechOpen is fantastic. The whole process of submitting an article and editing of the submitted article goes extremely smooth and fast, the number of reads and downloads of chapters is high, and the contributions are also frequently cited.",author:{id:"55578",name:"Antonio",surname:"Jurado-Navas",institutionString:null,profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRisIQAS/Profile_Picture_1626166543950",slug:"antonio-jurado-navas",institution:{id:"720",name:"University of Malaga",country:{id:null,name:"Spain"}}}},{id:"6",text:"It is great to work with the IntechOpen to produce a worthwhile collection of research that also becomes a great educational resource and guide for future research endeavors.",author:{id:"259298",name:"Edward",surname:"Narayan",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/259298/images/system/259298.jpeg",slug:"edward-narayan",institution:{id:"3",name:"University of Queensland",country:{id:null,name:"Australia"}}}}]},series:{item:{id:"24",title:"Sustainable Development",doi:"10.5772/intechopen.100361",issn:null,scope:"
\r\n\tThe topic on Economics is designed to disseminate knowledge around broad global economic issues. Original submissions will be accepted in English for applied and theoretical articles, case studies and reviews about the specific challenges and opportunities faced by the economies and markets around the world. The authors are encouraged to apply rigorous economic analysis with significant policy implications for developed and developing countries. Examples of subjects of interest will include, but are not limited to globalization, economic integration, growth and development, international trade, environmental development, country specific comparative analysis, technical innovation and knowledge management, political economy analysis, and banking and financial markets.
",coverUrl:"https://cdn.intechopen.com/series_topics/covers/87.jpg",hasOnlineFirst:!1,hasPublishedBooks:!1,annualVolume:11971,editor:{id:"327730",title:"Prof.",name:"Jaime",middleName:null,surname:"Ortiz",slug:"jaime-ortiz",fullName:"Jaime Ortiz",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0033Y00002zaOKZQA2/Profile_Picture_1642145584421",biography:"Dr. Jaime Ortiz holds degrees from Chile, the Netherlands, and the United States. He has held tenured faculty, distinguished professorship, and executive leadership appointments in several universities around the world. Dr. Ortiz has previously worked for international organizations and non-government entities in economic and business matters, and he has university-wide globalization engagement in more than thirty-six countries. He has advised, among others, the United Nations Development Program, Inter-American Development Bank, Organization of American States, Pre-investment Organization of Latin America and the Caribbean, Technical Cooperation of the Suisse Government, and the World Bank. Dr. Ortiz is the author, co-author, or editor of books, book chapters, textbooks, research monographs and technical reports, and refereed journal articles. He is listed in Who’s Who in the World, Who’s Who in America, Who’s Who in Finance and Business, Who’s Who in Business Higher Education, Who’s Who in American Education, and Who’s Who Directory of Economists. Dr. Ortiz has been a Fulbright Scholar and an MSI Leadership Fellow with the W.K. Kellogg Foundation. His teaching interests revolve around global economies and markets while his research focuses on topics related to development and growth, global business decisions, and the economics of technical innovation.",institutionString:null,institution:{name:"University of Houston",institutionURL:null,country:{name:"United States of America"}}},editorTwo:null,editorThree:null,series:{id:"22",title:"Business, Management and Economics",doi:"10.5772/intechopen.100359",issn:"2753-894X"},editorialBoard:[{id:"104262",title:"Dr.",name:"Chee-Heong",middleName:null,surname:"Quah",slug:"chee-heong-quah",fullName:"Chee-Heong Quah",profilePictureURL:"https://mts.intechopen.com/storage/users/104262/images/system/104262.jpg",institutionString:null,institution:{name:"University of Malaya",institutionURL:null,country:{name:"Malaysia"}}},{id:"236659",title:"Prof.",name:"Monica Violeta",middleName:null,surname:"Achim",slug:"monica-violeta-achim",fullName:"Monica Violeta Achim",profilePictureURL:"https://mts.intechopen.com/storage/users/236659/images/system/236659.jpg",institutionString:null,institution:{name:"Babeș-Bolyai University",institutionURL:null,country:{name:"Romania"}}},{id:"202039",title:"Dr.",name:"Nahanga",middleName:null,surname:"Verter",slug:"nahanga-verter",fullName:"Nahanga Verter",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bSCwtQAG/Profile_Picture_1643101901237",institutionString:null,institution:{name:"Mendel University Brno",institutionURL:null,country:{name:"Czech Republic"}}},{id:"107745",title:"Emeritus Prof.",name:"Panagiotis E.",middleName:null,surname:"Petrakis",slug:"panagiotis-e.-petrakis",fullName:"Panagiotis E. Petrakis",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRzzaQAC/Profile_Picture_1644221136992",institutionString:null,institution:{name:"National and Kapodistrian University of Athens",institutionURL:null,country:{name:"Greece"}}},{id:"196259",title:"Dr.",name:"Ryan Merlin",middleName:null,surname:"Yonk",slug:"ryan-merlin-yonk",fullName:"Ryan Merlin Yonk",profilePictureURL:"https://mts.intechopen.com/storage/users/196259/images/system/196259.jpg",institutionString:null,institution:{name:"American Institute for Economic Research",institutionURL:null,country:{name:"United States of America"}}}]},onlineFirstChapters:{paginationCount:8,paginationItems:[{id:"81557",title:"Object Tracking Using Adapted Optical Flow",doi:"10.5772/intechopen.102863",signatures:"Ronaldo Ferreira, Joaquim José de Castro Ferreira and António José Ribeiro Neves",slug:"object-tracking-using-adapted-optical-flow",totalDownloads:18,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Information Extraction and Object Tracking in Digital Video",coverURL:"https://cdn.intechopen.com/books/images_new/10652.jpg",subseries:{id:"24",title:"Computer Vision"}}},{id:"81558",title:"Thresholding Image Techniques for Plant Segmentation",doi:"10.5772/intechopen.104587",signatures:"Miguel Ángel Castillo-Martínez, Francisco Javier Gallegos-Funes, Blanca E. Carvajal-Gámez, Guillermo Urriolagoitia-Sosa and Alberto J. Rosales-Silva",slug:"thresholding-image-techniques-for-plant-segmentation",totalDownloads:20,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Information Extraction and Object Tracking in Digital Video",coverURL:"https://cdn.intechopen.com/books/images_new/10652.jpg",subseries:{id:"24",title:"Computer Vision"}}},{id:"81234",title:"Cognitive Visual Tracking of Hand Gestures in Real-Time RGB Videos",doi:"10.5772/intechopen.103170",signatures:"Richa Golash and Yogendra Kumar Jain",slug:"cognitive-visual-tracking-of-hand-gestures-in-real-time-rgb-videos",totalDownloads:40,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Information Extraction and Object Tracking in Digital Video",coverURL:"https://cdn.intechopen.com/books/images_new/10652.jpg",subseries:{id:"24",title:"Computer Vision"}}},{id:"80064",title:"Robust Template Update Strategy for Efficient Visual Object Tracking",doi:"10.5772/intechopen.101800",signatures:"Awet Haileslassie Gebrehiwot, Jesus Bescos and Alvaro Garcia-Martin",slug:"robust-template-update-strategy-for-efficient-visual-object-tracking",totalDownloads:64,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Information Extraction and Object Tracking in Digital Video",coverURL:"https://cdn.intechopen.com/books/images_new/10652.jpg",subseries:{id:"24",title:"Computer Vision"}}},{id:"80109",title:"Siamese-Based Attention Learning Networks for Robust Visual Object Tracking",doi:"10.5772/intechopen.101698",signatures:"Md. Maklachur Rahman and Soon Ki Jung",slug:"siamese-based-attention-learning-networks-for-robust-visual-object-tracking",totalDownloads:101,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Information Extraction and Object Tracking in Digital Video",coverURL:"https://cdn.intechopen.com/books/images_new/10652.jpg",subseries:{id:"24",title:"Computer Vision"}}},{id:"79005",title:"Smart-Road: Road Damage Estimation Using a Mobile Device",doi:"10.5772/intechopen.100289",signatures:"Izyalith E. Álvarez-Cisneros, Blanca E. Carvajal-Gámez, David Araujo-Díaz, Miguel A. Castillo-Martínez and L. Méndez-Segundo",slug:"smart-road-road-damage-estimation-using-a-mobile-device",totalDownloads:120,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Information Extraction and Object Tracking in Digital Video",coverURL:"https://cdn.intechopen.com/books/images_new/10652.jpg",subseries:{id:"24",title:"Computer Vision"}}},{id:"78576",title:"A Study on Traditional and CNN Based Computer Vision Sensors for Detection and Recognition of Road Signs with Realization for ADAS",doi:"10.5772/intechopen.99416",signatures:"Vinay M. Shivanna, Kuan-Chou Chen, Bo-Xun Wu and Jiun-In Guo",slug:"a-study-on-traditional-and-cnn-based-computer-vision-sensors-for-detection-and-recognition-of-road-s",totalDownloads:100,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Information Extraction and Object Tracking in Digital Video",coverURL:"https://cdn.intechopen.com/books/images_new/10652.jpg",subseries:{id:"24",title:"Computer Vision"}}},{id:"77617",title:"Adsorption-Semiconductor Sensor Based on Nanosized SnO2 for Early Warning of Indoor Fires",doi:"10.5772/intechopen.98989",signatures:"Nelli Maksymovych, Ludmila Oleksenko and George Fedorenko",slug:"adsorption-semiconductor-sensor-based-on-nanosized-sno2-for-early-warning-of-indoor-fires",totalDownloads:48,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Information Extraction and Object Tracking in Digital Video",coverURL:"https://cdn.intechopen.com/books/images_new/10652.jpg",subseries:{id:"24",title:"Computer Vision"}}}]},publishedBooks:{paginationCount:9,paginationItems:[{type:"book",id:"9959",title:"Biomedical Signal and Image Processing",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/9959.jpg",slug:"biomedical-signal-and-image-processing",publishedDate:"April 14th 2021",editedByType:"Edited by",bookSignature:"Yongxia Zhou",hash:"22b87a09bd6df065d78c175235d367c8",volumeInSeries:10,fullTitle:"Biomedical Signal and Image Processing",editors:[{id:"259308",title:"Dr.",name:"Yongxia",middleName:null,surname:"Zhou",slug:"yongxia-zhou",fullName:"Yongxia Zhou",profilePictureURL:"https://mts.intechopen.com/storage/users/259308/images/system/259308.jpeg",institutionString:"University of Southern California",institution:{name:"University of Southern California",institutionURL:null,country:{name:"United States of America"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9973",title:"Data Acquisition",subtitle:"Recent Advances and Applications in Biomedical Engineering",coverURL:"https://cdn.intechopen.com/books/images_new/9973.jpg",slug:"data-acquisition-recent-advances-and-applications-in-biomedical-engineering",publishedDate:"March 17th 2021",editedByType:"Edited by",bookSignature:"Bartłomiej Płaczek",hash:"75ea6cdd241216c9db28aa734ab34446",volumeInSeries:9,fullTitle:"Data Acquisition - Recent Advances and Applications in Biomedical Engineering",editors:[{id:"313277",title:"Dr.",name:"Bartłomiej",middleName:null,surname:"Płaczek",slug:"bartlomiej-placzek",fullName:"Bartłomiej Płaczek",profilePictureURL:"https://mts.intechopen.com/storage/users/313277/images/system/313277.jpg",institutionString:"University of Silesia",institution:{name:"University of Silesia",institutionURL:null,country:{name:"Poland"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9905",title:"Biometric Systems",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/9905.jpg",slug:"biometric-systems",publishedDate:"February 10th 2021",editedByType:"Edited by",bookSignature:"Muhammad Sarfraz",hash:"c730560dd2e3837a03407b3a86b0ef2a",volumeInSeries:8,fullTitle:"Biometric Systems",editors:[{id:"215610",title:"Prof.",name:"Muhammad",middleName:null,surname:"Sarfraz",slug:"muhammad-sarfraz",fullName:"Muhammad Sarfraz",profilePictureURL:"https://mts.intechopen.com/storage/users/215610/images/system/215610.jpeg",institutionString:"Kuwait University",institution:{name:"Kuwait University",institutionURL:null,country:{name:"Kuwait"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"8622",title:"Peptide Synthesis",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/8622.jpg",slug:"peptide-synthesis",publishedDate:"December 18th 2019",editedByType:"Edited by",bookSignature:"Jaya T. Varkey",hash:"de9fa48c5248dbfb581825b8c74f5623",volumeInSeries:0,fullTitle:"Peptide Synthesis",editors:[{id:"246502",title:"Dr.",name:"Jaya T.",middleName:"T",surname:"Varkey",slug:"jaya-t.-varkey",fullName:"Jaya T. Varkey",profilePictureURL:"https://mts.intechopen.com/storage/users/246502/images/11160_n.jpg",institutionString:"St. Teresa’s College",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"7497",title:"Computer Vision in Dentistry",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/7497.jpg",slug:"computer-vision-in-dentistry",publishedDate:"September 18th 2019",editedByType:"Edited by",bookSignature:"Monika Elzbieta Machoy",hash:"1e9812cebd46ef9e28257f3e96547f6a",volumeInSeries:7,fullTitle:"Computer Vision in Dentistry",editors:[{id:"248279",title:"Dr.",name:"Monika",middleName:"Elzbieta",surname:"Machoy",slug:"monika-machoy",fullName:"Monika Machoy",profilePictureURL:"https://mts.intechopen.com/storage/users/248279/images/system/248279.jpeg",institutionString:"Pomeranian Medical University",institution:{name:"Pomeranian Medical University",institutionURL:null,country:{name:"Poland"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"8633",title:"Novel Diagnostic Methods in Ophthalmology",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/8633.jpg",slug:"novel-diagnostic-methods-in-ophthalmology",publishedDate:"September 4th 2019",editedByType:"Edited by",bookSignature:"Anna Nowinska",hash:"da2c90e8db647ead30504defce3fb5d3",volumeInSeries:6,fullTitle:"Novel Diagnostic Methods in Ophthalmology",editors:[{id:"261466",title:"Dr.",name:"Anna",middleName:"Karolina",surname:"Nowińska",slug:"anna-nowinska",fullName:"Anna Nowińska",profilePictureURL:"https://mts.intechopen.com/storage/users/261466/images/system/261466.jpeg",institutionString:"Medical University of Silesia",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"7560",title:"Non-Invasive Diagnostic Methods",subtitle:"Image Processing",coverURL:"https://cdn.intechopen.com/books/images_new/7560.jpg",slug:"non-invasive-diagnostic-methods-image-processing",publishedDate:"December 19th 2018",editedByType:"Edited by",bookSignature:"Mariusz Marzec and Robert Koprowski",hash:"d92fd8cf5a90a47f2b8a310837a5600e",volumeInSeries:3,fullTitle:"Non-Invasive Diagnostic Methods - Image Processing",editors:[{id:"253468",title:"Dr.",name:"Mariusz",middleName:null,surname:"Marzec",slug:"mariusz-marzec",fullName:"Mariusz Marzec",profilePictureURL:"https://mts.intechopen.com/storage/users/253468/images/system/253468.png",institutionString:"University of Silesia",institution:{name:"University of Silesia",institutionURL:null,country:{name:"Poland"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"7218",title:"OCT",subtitle:"Applications in Ophthalmology",coverURL:"https://cdn.intechopen.com/books/images_new/7218.jpg",slug:"oct-applications-in-ophthalmology",publishedDate:"September 19th 2018",editedByType:"Edited by",bookSignature:"Michele Lanza",hash:"e3a3430cdfd6999caccac933e4613885",volumeInSeries:2,fullTitle:"OCT - Applications in Ophthalmology",editors:[{id:"240088",title:"Prof.",name:"Michele",middleName:null,surname:"Lanza",slug:"michele-lanza",fullName:"Michele Lanza",profilePictureURL:"https://mts.intechopen.com/storage/users/240088/images/system/240088.png",institutionString:'University of Campania "Luigi Vanvitelli"',institution:{name:'University of Campania "Luigi Vanvitelli"',institutionURL:null,country:{name:"Italy"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"6692",title:"Medical and Biological Image Analysis",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/6692.jpg",slug:"medical-and-biological-image-analysis",publishedDate:"July 4th 2018",editedByType:"Edited by",bookSignature:"Robert Koprowski",hash:"e75f234a0fc1988d9816a94e4c724deb",volumeInSeries:1,fullTitle:"Medical and Biological Image Analysis",editors:[{id:"50150",title:"Prof.",name:"Robert",middleName:null,surname:"Koprowski",slug:"robert-koprowski",fullName:"Robert Koprowski",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002aYTYNQA4/Profile_Picture_1630478535317",institutionString:null,institution:{name:"University of Silesia",institutionURL:null,country:{name:"Poland"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null}]},testimonialsList:[{id:"27",text:"The opportunity to work with a prestigious publisher allows for the possibility to collaborate with more research groups interested in animal nutrition, leading to the development of new feeding strategies and food valuation while being more sustainable with the environment, allowing more readers to learn about the subject.",author:{id:"175967",name:"Manuel",surname:"Gonzalez Ronquillo",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/175967/images/system/175967.png",slug:"manuel-gonzalez-ronquillo",institution:{id:"6221",name:"Universidad Autónoma del Estado de México",country:{id:null,name:"Mexico"}}}},{id:"18",text:"It was great publishing with IntechOpen, the process was straightforward and I had support all along.",author:{id:"71579",name:"Berend",surname:"Olivier",institutionString:"Utrecht University",profilePictureURL:"https://mts.intechopen.com/storage/users/71579/images/system/71579.png",slug:"berend-olivier",institution:{id:"253",name:"Utrecht University",country:{id:null,name:"Netherlands"}}}},{id:"8",text:"I work with IntechOpen for a number of reasons: their professionalism, their mission in support of Open Access publishing, and the quality of their peer-reviewed publications, but also because they believe in equality.",author:{id:"202192",name:"Catrin",surname:"Rutland",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/202192/images/system/202192.png",slug:"catrin-rutland",institution:{id:"134",name:"University of Nottingham",country:{id:null,name:"United Kingdom"}}}}]},submityourwork:{pteSeriesList:[{id:"14",title:"Artificial Intelligence",numberOfPublishedBooks:9,numberOfPublishedChapters:90,numberOfOpenTopics:6,numberOfUpcomingTopics:0,issn:"2633-1403",doi:"10.5772/intechopen.79920",isOpenForSubmission:!0},{id:"7",title:"Biomedical Engineering",numberOfPublishedBooks:12,numberOfPublishedChapters:104,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2631-5343",doi:"10.5772/intechopen.71985",isOpenForSubmission:!0}],lsSeriesList:[{id:"11",title:"Biochemistry",numberOfPublishedBooks:32,numberOfPublishedChapters:320,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2632-0983",doi:"10.5772/intechopen.72877",isOpenForSubmission:!0},{id:"25",title:"Environmental Sciences",numberOfPublishedBooks:1,numberOfPublishedChapters:12,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2754-6713",doi:"10.5772/intechopen.100362",isOpenForSubmission:!0},{id:"10",title:"Physiology",numberOfPublishedBooks:11,numberOfPublishedChapters:141,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2631-8261",doi:"10.5772/intechopen.72796",isOpenForSubmission:!0}],hsSeriesList:[{id:"3",title:"Dentistry",numberOfPublishedBooks:8,numberOfPublishedChapters:133,numberOfOpenTopics:2,numberOfUpcomingTopics:0,issn:"2631-6218",doi:"10.5772/intechopen.71199",isOpenForSubmission:!0},{id:"6",title:"Infectious Diseases",numberOfPublishedBooks:13,numberOfPublishedChapters:113,numberOfOpenTopics:3,numberOfUpcomingTopics:1,issn:"2631-6188",doi:"10.5772/intechopen.71852",isOpenForSubmission:!0},{id:"13",title:"Veterinary Medicine and Science",numberOfPublishedBooks:11,numberOfPublishedChapters:107,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2632-0517",doi:"10.5772/intechopen.73681",isOpenForSubmission:!0}],sshSeriesList:[{id:"22",title:"Business, Management and Economics",numberOfPublishedBooks:1,numberOfPublishedChapters:19,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2753-894X",doi:"10.5772/intechopen.100359",isOpenForSubmission:!0},{id:"23",title:"Education and Human Development",numberOfPublishedBooks:0,numberOfPublishedChapters:5,numberOfOpenTopics:1,numberOfUpcomingTopics:1,issn:null,doi:"10.5772/intechopen.100360",isOpenForSubmission:!0},{id:"24",title:"Sustainable Development",numberOfPublishedBooks:0,numberOfPublishedChapters:17,numberOfOpenTopics:5,numberOfUpcomingTopics:0,issn:null,doi:"10.5772/intechopen.100361",isOpenForSubmission:!0}],subseriesList:[],annualVolumeBook:{},thematicCollection:[],selectedSeries:null,selectedSubseries:null},seriesLanding:{item:null},libraryRecommendation:{success:null,errors:{},institutions:[]},route:{name:"profile.detail",path:"/profiles/191635",hash:"",query:{},params:{id:"191635"},fullPath:"/profiles/191635",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()